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1. Introduction 
This report describes and summarises results 
from the nineteenth proficiency test trial 
conducted by the National Food Institute (DTU 
Food) as the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR). This 
proficiency test focuses on antimicrobial 
susceptibility testing (AST) of Salmonella and 
Campylobacter and is the ninth External Quality 
Assurance System (EQAS) conducted for these 
microorganisms (the first was EQAS 2006). In 
addition, the proficiency test includes 
categorization of the relevant Salmonella 
strains as presumptive AmpC-, ESBL-, or 
carbapenemase producing organisms, and 
identification of the Campylobacter species as 
either C. jejuni or C. coli,  
In addition, for the seventh time, an optional 
element was included, consisting of genotypic 
characterization by PCR/sequencing of 
antimicrobial resistance genes. This optional 
component included characterization of genes 
related to production of AmpC, ESBL- and 
carbapenemases in the Salmonella test strains. 
This EQAS aims to: i) monitor the quality of 
AST results produced by National Reference 
Laboratories (NRL-AR), ii) identify laboratories 
which may need assistance to improve their 
performance in AST, and iii) determine possible 
topics for further research or collaboration. 
In reading this report, the following important 
considerations should be taken into account: 
1) Expected results were generated by 
performing Minimum Inhibitory Concentration 
(MIC) determinations for all test strains in two 
different occasions at the Technical University 
of Denmark, National Food Institute (DTU 
Food). These results were then verified by the 
United States Food and Drug Administration 
(FDA), Centre for Veterinary Medicine. Finally, a 
fourth MIC determination was performed at 
DTU Food after preparation of the agar stab 
culture for shipment to participants to confirm 
that the vials contained the correct strains with 
the expected MIC values. 
2) Evaluation is based on interpretations of 
AST values determined by the participants. This 
is in agreement with the method used by 
Member States (MS) to report AST data to the 
European Food Safety Authority (EFSA), and 
complies with the main objective of this EQAS, 
i.e. to evaluate and improve the comparability of 
surveillance data on antimicrobial susceptibility 
of Salmonella and Campylobacter reported to 
EFSA by different laboratories, as stated in the 
protocol. 
3) The EURL-AR network agreed on setting the 
accepted deviation level for laboratory 
performance on AST to 5%. For the optional 
genotypic characterisation, no specific 
acceptance level has been set. 
Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analyzed in a self-evaluation procedure 
performed by the participant including also 
considerations related to any corrective actions 
introduced in the laboratory. Note, that since 
methods used for MIC determination have 
limitations, it is not considered a mistake to 
obtain a one-fold dilution difference in the MIC 
of a specific antimicrobial when testing the 
same strains. If, however, the expected MIC is 
close to the breakpoint value for categorizing 
the strain as susceptible or resistant, a one-fold 
dilution difference - which is acceptable - may 
result in two different interpretations, i.e. the 
same strain can be categorized as susceptible 
and resistant. This result will be evaluated as 
correct in one case but incorrect when the 
evaluation is based on interpretation of MIC 
values. This report is based on evaluation of 
AST interpretations, therefore some participants 
may find their results classified as incorrect 
even though the actual MIC they reported is 
only a one-fold dilution different from the 
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expected MIC. In these cases, the participants 
should be confident about the good quality of 
their performance of AST by MIC. In the 
organization of the EQAS, we try to avoid these 
situations by choosing test strains with MIC 
values distant from the breakpoints for 
resistance, which is not always feasible for all 
strains and all antimicrobials. Therefore, the 
EURL-AR network unanimously established in 
2008 that if there are less than 75% correct 
results for a specific strain/antimicrobial 
combination, the reasons for this situation must 
be further examined and, on selected occasions 
explained in details case by case, these results 
may subsequently be omitted from the 
evaluation report.  
This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRL-ARs. 
This group meets annually at the EURL-AR 
workshop. 
All conclusions presented in this report are 
publically available. Participating laboratories 
are identified by codes and each code is known 
only by the corresponding laboratory. The full 
list of laboratory codes is confidential 
information known only by relevant 
representatives of the EURL-AR and the EU 
Commission.  
The EURL-AR is accredited by DANAK as 
provider of proficiency testing (accreditation no. 
516); working with zoonotic pathogens and 
indicator organisms as bacterial isolates 
(identification, serotyping and antimicrobial 
susceptibility testing). 
2. Materials and Methods  
2.1 Participants in EQAS 2015 
A pre-notification (App. 1) to announce the 
EURL-AR EQAS on AST of Salmonella and 
Campylobacter was distributed on the 23th June 
2015 by e-mail to the 43 NRLs in the EURL-AR-
network including all EU countries and Iceland, 
Norway, Serbia, Switzerland and Turkey. All EU 
MS as well as Iceland, Norway, and Switzerland 
were represented as participants for both 
Salmonella and Campylobacter. In addition to 
the AST of Salmonella and Campylobacter, an 
optional genotypic characterization by 
PCR/sequencing of antimicrobial resistance 
genes of the AmpC-, ESBL- and 
carbapenemase-producing Salmonella test 
strains was offered.  
Appendix 2 shows that 29 of the 34 
participating NRLs were appointed by the 
individual Member States’ Competent Authority. 
Five additional laboratories were included; one 
from each of the following countries: Iceland, 
the Netherlands, Norway, Spain, and 
Switzerland. These were invited to take part in 
the EQAS 2015 on the basis of their 
participation in previous EQAS iterations and/or 
affiliation to the EU network. These laboratories 
were charged a fee for their participation in the 
EQAS, whereas the NRLs from EU Member 
States participated free of charge. 
Figure 1 illustrates that of the 31 participating 
countries, all tested both Salmonella and 
Campylobacter. Nine laboratories participated 
in the optional genotypic characterisation of the 
ESC-producing Salmonella test strains (not 
illustrated in Figure 1; see Appendix 2). 
The results from the NRLs designated by the 
MS are presented and evaluated in this report 
in addition to national reference laboratories in 
affiliated non-MS; i.e. results from 31 countries 
consisting of 31 laboratories submitting 
Salmonella results and 31 laboratories 
submitting Campylobacter results. Results from 
the two laboratories not designated by the MS 
but enrolled on equal terms as these are not 
further presented or evaluated in this report.
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Figure 1: Participating countries that performed antimicrobial susceptibility testing of Salmonella 
and Campylobacter. 
2.2 Strains  
Eight Salmonella strains and eight 
Campylobacter strains were selected for this 
trial among isolates from the strain collection at 
DTU Food on the basis of antimicrobial 
resistance profiles and MIC values. For quality 
assurance purposes, one strain per bacterial 
species has been included in all EQAS 
iterations performed to date, representing an 
internal control. 
Prior to distribution of the strains, AST was 
performed on the Salmonella and 
Campylobacter strains at DTU Food and 
verified by the US Food and Drug 
Administration (FDA). When MIC-values were 
not in agreement but varied +/- one MIC-step, 
the value obtained by DTU Food was selected 
as the reference value. The obtained MIC 
values served as reference for the test strains 
(App. 3a and 3b). Results from the following 
antimicrobials were not verified by FDA: 
cefepime, cefotaxime, cefotaxime/clavulanic 
acid, ceftazidime, ceftazidime/clavulanic acid, 
colistin, ertapenem, imipenem, meropenem, 
temocillin, tigecycline and trimethoprim for 
Salmonella and furthermore, streptomycin for 
Campylobacter. 
Reference strains Escherichia coli CCM 3954 
(ATCC 25922) and Campylobacter jejuni CCM 
6214 (ATCC 33560) were provided to new 
participating laboratories with instructions to 
store and maintain them for quality assurance 
purposes and future EQAS trials. 
2.3 Antimicrobials  
The antimicrobials tested in this EQAS are 
listed in the protocol (App. 4b).  
The antimicrobials tested correspond to the 
panel of antimicrobials listed in Decision 
2013/652/EU.  
Guidelines for performing AST were set 
according to the Clinical and Laboratory 
Standards Institute (CLSI) document; M7-A10 
(2015) “Methods for Dilution Antimicrobial 
Susceptibility Tests for Bacteria That Grow 
Aerobically; Approved Standard - Tenth 
Edition”; M100-S25 (2015) “Performance 
Standards for Antimicrobial Susceptibility 
Testing” (Twenty-Fifth Informational 
Supplement) and document VET01-A4 (2013) 
“Performance Standards for Antimicrobial Disk 
and Dilution Susceptibility Tests for Bacterial 
                                                            
 
7 
 
Isolated From Animals” (Approved Standard – 
Fourth Edition). 
MIC results were interpreted by using the 
interpretative criteria listed in Decision 
2013/652/EU. Where values were not available, 
the list of interpretative criteria was 
supplemented with CLSI-interpretative criteria 
as described and indicated in the protocol (App. 
4). No interpretative criteria were available to 
determine the interpretation of MIC-values from 
testing of azithromycin, cefepime and temocillin. 
Results of ESC detection tests were interpreted 
according to the at deadline most recent EFSA 
recommendations (EFSA Journal 2012; 
10(6):2742).  
The selection of antimicrobials used in the trial 
for Salmonella were: ampicillin (AMP), 
azithromycin (AZI), cefepime (FEP), cefotaxime 
(FOT), cefotaxime/clavulanic acid (FOT/Cl), 
cefoxitin (FOX), ceftazidime (TAZ), 
ceftazidime/clavulanic acid (TAZ/Cl), 
chloramphenicol (CHL), ciprofloxacin (CIP), 
colistin (COL), ertapenem (ERT), gentamicin 
(GEN), imipenem (IMI), meropenem (MER), 
nalidixic acid (NAL), sulfonamides 
(sulfamethoxazole) (SMX), tetracycline (TET), 
tigecycline (TGC), temocillin (TRM) and 
trimethoprim (TMP). 
Minimum Inhibitory Concentration (MIC) 
determination of the Salmonella test strains was 
performed using the Sensititre system from 
Trek Diagnostic Systems Ltd, UK. For ESC 
confirmatory test, the analysis included MIC 
determination by microbroth dilution.  
For Campylobacter the following antimicrobials 
were included: ciprofloxacin (CIP), erythromycin 
(ERY), gentamicin (GEN), nalidixic acid (NAL), 
streptomycin (STR), and tetracycline (TET). 
MIC determination for the Campylobacter 
testing, was performed using the Sensititre 
systems from Trek Diagnostic Systems Ltd, UK, 
according to guidelines from the CLSI 
document M45-A2 (2010) “Methods for 
Antimicrobial Dilution and Disk Susceptibility 
Testing of Infrequently Isolated or Fastidious 
Bacteria” (Approved Guideline – Second 
Edition) and VET01-S2 (2013) “Performance 
Standards for Antimicrobial Disk and Dilution 
Susceptibility Tests for Bacterial Isolated From 
Animals” (Second Informational Supplement). 
Participants of the Campylobacter EQAS were 
additionally requested to identify the species of 
the Campylobacter spp. as either C. jejuni or C. 
coli. 
2.4 Distribution 
On the 14th October 2015, bacterial strains in 
agar stab cultures (Salmonella spp.) or charcoal 
swabs in transport media (Stuarts) 
(Campylobacter spp.) together with a welcome 
letter (App. 4a) were dispatched in double pack 
containers (class UN 6.2) to the participating 
laboratories. The shipment (UN3373, biological 
substances category B) was sent according to 
International Air Transport Association (IATA) 
regulations.  
2.5 Procedure 
Protocols and all relevant information were 
uploaded on the EURL-AR website 
(http://www.eurl-ar.eu), thereby EQAS 
participants could access necessary information 
at any time.  
Participants were instructed to subculture 
charcoal swabs immediately, store the agar 
stabs at 4ºC (dark) and the freeze-dried strains 
cool and dark until performance of AST. 
Information related to the handling of the test 
strains and reference strains (App. 4b, c, d, e) 
was made available. Participants receiving an 
ATCC reference strain were requested to save 
and maintain this strain for future proficiency 
tests. 
The participants were instructed to apply the 
interpretative criteria listed in the protocol (App. 
4). Instructions for interpretation of AST results 
allowed for categorization of results as resistant 
or susceptible. Categorisations as ‘intermediate’ 
were not accepted.  
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The EURL-AR is aware that there are two 
different types of interpretative criteria of 
results, clinical breakpoints and epidemiological 
cut-off values. The terms ‘susceptible’, 
‘intermediate’ and ‘resistant’ should be reserved 
for classifications made in relation to the 
therapeutic application of antimicrobial agents. 
When reporting data using epidemiological cut-
off values, bacteria should be reported as ‘wild-
type’ or ‘non-wild-type’ (Schwarz et al., 2010). 
Due to the different methods of AST used by 
the participants and also to simplify the 
interpretation of results, throughout this report, 
we will still maintain the terms susceptible and 
resistant, even in cases where we are referring 
to wild-type and non-wild-type strains. 
As regards the method for performing the 
antimicrobial susceptibility testing, the protocol 
referred to Decision 2013/652/EU and 
instructed participants to perform a dilution 
method, i.e. microbroth dilution or agar dilution. 
Results obtained by methods not complying 
with the description in Decision 2013/652/EU 
were not included in the present analysis. 
A mandatory part of the proficiency test was to 
detect ESC-producing strains and interpret 
results according to the most recent EFSA 
recommendations (EFSA Journal 2012; 
10(6):2742) as described in the protocol.  
Results from QC reference strains would 
consist of MIC values for the reference strains 
E. coli (ATCC 25922) and C. jejuni (ATCC 
33560). The results were evaluated towards the 
quality control ranges according to the relevant 
guidelines; i.e. the CLSI documents VET01-S2 
(2013) or M100-S25 (2015) (App. 5). 
For the optional genotypic characterisation of 
the ESC-producing Salmonella test strains, 
participating laboratories were requested to 
report the genes conferring resistance to 
extended-spectrum beta lactam antimicrobials. 
The organizers, however, decided to include 
none-ESC TEM-genes resulting in blaTEM-1 
registered as an expected gene, also. The 
genes listed in the table in the protocol (App. 
4b) were included in the test. Identification of 
additional genes not listed in the protocol was 
not evaluated by the database. The results 
were evaluated based on the actual genes and 
variants identified. 
The participating laboratories were encouraged 
to use their own laboratory’s method(s) for the 
genotypic characterisation. The expected 
results for this component of the EQAS were 
obtained by whole-genome-sequencing and 
subsequent analysis using the ResFinder 2.1 
platform available at 
http://cge.cbs.dtu.dk/services/ResFinder/. The 
positive identification of genes was not verified 
elsewhere. 
All participating laboratories were invited to 
enter the obtained results into an electronic 
record sheet at the EURL-AR web-based 
database through a secured individual login and 
password. The record sheet contained space 
for reporting the results obtained for the QC 
reference strains. Alternatively, it was offered 
the possibility to fill-in a record sheet (provided 
with the protocol) and to send it to the EURL-
AR by fax, mail or email. 
In addition, participants were encouraged to 
complete an evaluation form available at the 
EURL-AR database with the aim to improve 
future EQAS trials. 
The database was finally closed and 
evaluations were made available to participants 
on the 9th December 2015. After this date, the 
participants were invited to login to retrieve an 
individual, database-generated report which 
contained an evaluation of the submitted results 
including possible deviations from the expected 
interpretations. Deviations in the interpretation 
as resistant or susceptible were categorised as 
‘incorrect’, as were also deviations concerning 
confirmation of an isolate as extended spectrum 
beta-lactamase- (ESBL-), ampC- or 
carbapenemase-producer. 
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3. Results 
The participants were asked to report results, 
i.e. MIC values and the categorisation as 
resistant or susceptible. Only the categorisation 
was evaluated, whereas the MIC values were 
used as supplementary information. 
3.1 Data omitted from the report 
As mentioned in the introduction, the EURL-AR 
network established that data should be 
examined and possibly omitted from the 
general analysis if there are less than 75% 
correct results based on strain/antimicrobial 
combination (see Appendix 8 for an overview of 
correct/incorrect results). In the present EQAS 
this occurred in two cases which have been 
examined and consequently omitted from the 
analysis; 1) S10.4/imipenem (expected 
interpretation was ‘resistant’, however, 30% (9 
laboratories) found the strain susceptible to 
imipenem. All but one of the deviating 
interpretations were based on MIC values two 
steps from the expected, one was three steps 
from the expected; 2) C10.4/tetracycline 
(expected interpretation was ‘susceptible’, 
however, 26% of participants found the strain 
‘resistant’ to tetracycline. All deviating 
interpretations were based on MIC values only 
one step from the expected. Both these 
combinations were subsequently omitted from 
further analysis. 
3.2 Methods  
The agar dilution method and MIC 
determination were evaluated together as they 
are both quantitative methods giving results 
corresponding to the MIC of the bacterial strain 
tested.  
In the Salmonella as well as the Campylobacter 
trial, 30 laboratories performed microbroth 
dilution and one performed agar dilution. 
With the aim to conclude on the strain’s 
presumptive ESBL, AmpC or carbapenemase 
phenotype, two panels of antimicrobials were 
included in the testing of the Salmonella strains. 
The test strains found resistant to cefotaxime, 
ceftazidime or meropenem on the first panel 
were additionally tested on the second panel 
according to the protocol indications.  
3.3 Deviations, overall 
The list of deviations is shown in Appendix 8a 
and 8b. Figure 2 shows the total percentage of 
deviations from the expected results of AST 
performed by participating laboratories. The 
internal control strains mainly followed the trend 
in deviation level of the different EQAS trials 
(Figure 2). The deviation level in 2015 is 
acceptable for both the Salmonella and the 
Campylobacter trials. For the current EQAS, for 
both microorganisms, it appears that there has 
been a decrease in the level of deviations, to 
0.7% for Salmonella and 1.6% for 
Campylobacter in 2015 from levels at 2.4% and 
4.0%, respectively in 2014.  
3.3.1 Salmonella trial  
For the Salmonella strains, 99.3% of the AST’s 
were interpreted correctly. The number of AST’s 
performed and the percentage of correct results 
for the individual strains in the EQAS, are listed 
in Table 1. Variations of obtained correct results 
ranged from 98.5-99.8% between the 
Salmonella strains. Table 2 illustrates the 
percentage of correct AST per antimicrobial by 
bacterial species. The level of correct AST was 
at 97.8% (tigecycline) or above, for all the 
Salmonella test strains.  
ESC-producing Salmonella test strains 
Confirmation of beta-lactamase production is a 
mandatory component of this EQAS.  
According to the protocol, which was based on 
the EFSA recommendations, the confirmatory 
test for ESC-production requires use of both 
cefotaxime (FOT) and ceftazidime (TAZ) alone 
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Figure 2: A comparison between the EURL-AR EQAS’s since 2006, showing the total percentage of deviations 
for antimicrobial susceptibility testing performed by participating laboratories.  
and in combination with a -lactamase inhibitor. 
The MIC value for either antimicrobial agent 
(FOT or TAZ) tested in combination with 
clavulanic acid should be compared to the 
corresponding MIC when tested alone. Synergy 
is indicated if a three dilution steps difference is 
observed between the two MIC values (i.e. if 
the FOT:CTX/Cl or TAZ:TAZ/Cl ratio 8) (CLSI 
M100 Table 2A; Enterobacteriaceae). 
Participants were instructed to test strains 
presenting resistance to cefotaxime (FOT), 
ceftazidime (TAZ or meropenem (MERO) on 
the second panel of antimicrobials. 
The classification of the phenotypic results was 
based on the most recent EFSA 
recommendations (EFSA 2012), indicating: 
 Presumptive ESBL-phenotype: strains 
with positive synergy test, susceptible to 
cefoxitin and resistant to cefepime 
 Presumptive ESBL+pAmpC-phenotype: 
strains with positive or negative synergy 
test, resistant to cefoxitin and resistant to 
cefepime 
 Presumptive pAmpC phenotype: strains 
with negative synergy test resistant to 
cefoxitin and susceptible to cefepime 
 Presumptive carbapenemase phenotype: 
strain resistant to meropenem 
 Unusual phenotype: any other 
combinations 
In this EQAS, all laboratories uploaded results 
for the strains exhibiting resistance to the 
cephalosporins tested. 
The strains S-10.3, S-10.7 and S-10.8 were 
ESBL-producers, and S-10.4 was a 
carbapenemase-producer. Note that when 
categorizing the presumptive phenotypes, the 
interpretation of the cefepime result had to be 
disregarded, as no interpretative criteria were 
available.  
In total, the categorization as ESBL-, pAmpC- 
or carbapenemase-producer was correct in 
almost all cases; i.e. out of 248 reported results, 
three were incorrect. The deviating results were 
presented by three different laboratories (#39, 
#56, and #60). For laboratory #39, the reported 
phenotypic results do not explain the selected 
presumptive phenotype for S-10.4 as ‘unusual 
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Table 1. The number of AST performed and the percentage of correct results for each strain of Salmonella and 
Campylobacter. 
EQAS 2015 – Salmonella  EQAS 2015 – Campylobacter 
Test strain AST in total % correct  Test strain AST in total % correct 
S-10.1 400 99.3  C-10.1 (C. jejuni) 185 97.3 
S-10.2 400 99.8  C-10.2 (C. coli) 186 98.4 
S-10.3 587 98.8  C-10.3 (C. jejuni) 186 97.3 
S-10.4 552 99.6  C-10.4 (C. coli) 155 100.0 
S-10.5 398 98.5  C-10.5 (C. jejuni) 186 98.4 
S-10.6 399 99.5  C-10.6 (C. coli) 185 98.4 
S-10.7 585 99.1  C-10.7 (C. coli) 186 97.8 
S-10.8 584 99.7  C-10.8 (C. jejuni) 186 100.0 
 
Table 2: Percentage of correct antimicrobial 
susceptibility tests per antimicrobial by 
microorganism.  
Antimicrobial Salmonella Campylobacter 
Ampicillin 99.2 - 
Cefotaxime 100.0 - 
Cefoxitin 99.2 - 
Ceftazidime 99.5 - 
Chloramphenicol 99.6 - 
Ciprofloxacin 98.8 99.6 
Colistin 98.0 - 
Ertapenem 100.0 - 
Erythromycin - 99.6 
Gentamicin 99.6 97.6 
Imipenem 100.0 - 
Meropenem 100.0 - 
Nalidixic acid 99.6 98.0 
Streptomycin - 97.2 
Sulphonamides 98.4 - 
Tetracycline 99.6 98.6 
Tigecycline 97.8 - 
Trimethoprim 99.2 - 
 
phenotype’. As follow-up, the laboratory 
reported that the cause for the incorrect 
categorization was based on the laboratory 
SOP not being strictly followed (the SOP clearly 
states that resistance to meropenem leads to 
‘presumptive carbapenemase phenotype’). For 
laboratory #56 and #60, however, the deviating 
results were caused by an incorrect result as 
resistant for cefoxitin (#56; S-10.7), and 
laboratory #60 commented that the positive 
synergy test and susceptibility to cefoxitin for 
strain S-10.3 indicated presumptive ESBL. The 
laboratory stated that the cefepime MIC value is 
a little lower than they usually see for this 
profile, and together with the fact that the strain 
is ceftazidime sensitive, they concluded that the 
strain was ‘unusual phenotype’.  
3.3.2 Campylobacter trial 
For the Campylobacter strains, 98.4% of AST’s 
were correctly tested. Table 1 presents that the 
variation in the obtained correct results ranged 
from 97.3-100% and Table 2 illustrates that the 
percentage of correct AST per antimicrobial 
was above 97.2% for the Campylobacter test 
strains with streptomycin exhibiting the lowest 
level. 
The participants were requested to identify the 
Campylobacter species. All 31 laboratories 
delivered in total 248 results of which one 
identification was incorrect (laboratory #34). 
The incorrect species identification did not lead 
to incorrect AST results for this laboratory and 
strain. 
3.4 Deviations by laboratory 
Figure 3 and 4 illustrate the percentage of 
deviations for each participating laboratory. The 
laboratories are ranked according to their 
performance determined by the percentage of 
deviating results in the antimicrobial 
susceptibility tests. 
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Table 3: Overview of ESBL-, pAmpC- and carbapenemase-producing Salmonella test strains and proportion of 
laboratories that obtained the expected result; number and percentages of laboratories which correctly detected and 
confirmed the ESBL-, pAmpC- and carbapenemase-producing Salmonella strains. Fields shaded in grey with numbers in 
italics indicate an unexpected result. 
 Strain S-10.3 Strain S-10.4 Strain S-10.7 Strain S-10.8 
ESC-genes harboured in the test strain 
blaTEM-1 
blaCTX-M-9 
blaTEM-1 
blaOXA-48 
blaTEM-1 
blaSHV-12 
blaCTX-M-15 
blaTEM-52 
ESBL-, pAmpC- and carbapenemase-producing 
strain – expected results 
ESBL carbapenemase ESBL ESBL 
Obtained 
results 
Confirmed ESBL-producer 30/31 (97%) - 30/31 (97%) 31/31 (100%) 
Confirmed ESBL + pAmpC-producer - - 1/31 (3%) - 
Confirmed pAmpC-producer - - - - 
Confirmed carbapenemase-producer - 30/31 (97%) - - 
Confirmed unusual phenotype 1/31 (3%) 1/31 (3%) - - 
Not ESBL-, pAmpC-  
or carbapenemase-producing - - - - 
 
 
Figure 3: Individual participants’ deviations in percent of their total number of Salmonella AST’s.  
 
Figure 4: Individual participants’ deviations in percent of their total number of Campylobacter AST’s. 
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Table 4 Obtained values for AST of E. coli ATCC 25922. 
AMP; ampicillin, FEP; cefepime FOT; cefotaxime, FOX; 
cefoxitin, TAZ; ceftazidime, CHL; chloramphenicol, CIP; 
ciprofloxacin, COL; colistin, ERT: ertapenem, GEN; 
gentamicin, IMI; imipenem, MER; meropenem, NAL; 
nalidixic acid, SMX; sulphonamides, TET; tetracycline, 
TGC; tigecycline, TMP; trimethoprim. 
MIC determination E. coli ATCC 25922 
Antimicrobial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below 
lower QC 
limit 
Above upper 
QC limit 
Panel 1, AMP 0/29 (0%) - - 
Panel 1, FOT 0/27 (0%) - - 
Panel 1, TAZ 0/28 (0%) - - 
Panel 1, CHL 0/29 (0%) - - 
Panel 1, CIP 1/29 (3%) - 1 step 
Panel 1, COL 0/29 (0%) - - 
Panel 1, GEN 0/29 (0%) - - 
Panel 1, MER 0/28 (0%) - - 
Panel 1, NAL 0/29 (0%) - - 
Panel 1, SMX 1/28 (4%) - 1 step 
Panel 1, TET 0/29 (0%) - - 
Panel 1, TGC 0/28 (0%) - - 
Panel 1, TMP 3/29 (10%) 1 step - 
Panel 2, FEP 1/24 (4%) - 2 steps 
Panel 2, FOT 1/24 (4%) - 1 steps 
Panel 2, FOX 0/25 (0%) - - 
Panel 2, TAZ 0/25 (0%) - - 
Panel 2, ERT 0/25 (0%) - - 
Panel 2, IMI 0/25 (0%) - - 
Panel 2, MER 0/25 (0%) - - 
Table 5 Obtained values for AST of C. jejuni ATCC 33560. 
CIP; ciprofloxacin, ERY; erythromycin, GEN; gentamicin, 
NAL; nalidixic acid, TET; tetracycline. 
MIC determination C. jejuni ATCC 33560 
Antimicrobial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below 
lower QC 
limit 
Above upper 
QC limit 
CIP 1/29 (3%) - 1 step 
ERY 0/29 (0%) - - 
GEN 3/28 (11%) 2 steps - 
NAL 0/28 (0%) - - 
TET 2/28 (7%) 1 step 2 steps 
 
3.4.1 Salmonella trial  
All 31 participating laboratories obtained a 
result within the acceptance limit at 5% 
deviations for the Salmonella strains. The 
maximum percentage of deviations was at 
4.1%, presenting a very good result across the 
EURL-AR network. 
3.4.2 Campylobacter trial 
In the Campylobacter trial, most laboratories 
performed very well. Applying the 5% 
acceptance threshold, 28 of 31 participating 
laboratories performed acceptably, with 24 
laboratories having no deviations (Figure 4). 
Three laboratories present a deviation level 
above the 5% acceptance level (#36, #39, and 
#42). Of these, one laboratory with a deviation 
level at 21.3% (#36) was regarded as an outlier. 
3.5 Deviations by reference strains  
In the following section, deviations are defined 
as results of antimicrobial susceptibility tests on 
the reference strain that are outside the quality 
control (QC) acceptance intervals (App. 5).  
Obtained values from the participants’ testing of 
the QC strains are listed in Appendix 6a and 6b, 
and in Table 4 and 5. For both the Salmonella 
and Campylobacter trial, 29 laboratories 
uploaded data from QC-testing on the relevant 
reference strain. 
Appendix 6a indicates that of the 29 
laboratories submitting AST-results for the 
reference strain E. coli ATCC 25922, six 
laboratories produced in all seven values 
outside the QC-limit. Table 4 illustrates the 
obtained results which are fully presented in 
Appendix 6a.  
Table 5 presents the proportion of laboratories 
with results for the C. jejuni reference strain 
ATCC 33560 below or above the QC interval. 
six deviations were seen from five different 
laboratories. 
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Figure 5: Individual participants’ deviations in percent of 
their total number of results from the genotypic 
characterization.  
3.6 Genotypic characterisation 
For the optional genotypic characterisation of 
the ESC-producing Salmonella test strains, nine 
laboratories participated. In Appendix 9, 
information is collected on detected genes, 
genes which were tested but not detected, 
primers used, and references for the method 
used. One laboratory performed whole genome 
sequencing of the ESC-producing Salmonella 
whereas the remaining eight laboratories 
indicated the use of various types of 
conventional PCR to identify the relevant 
genes. 
Table 6 indicate the obtained results, both on 
gene and variant level. Moreover, Figure 5 
indicates that two discordant results related to 
the gene variant were submitted by laboratory 
#21. CTX-M-15 belongs to the CTX M-1-group, 
however, it is not clear if this was the 
background for the deviation. 
Table 6: Results from the participation of nine laboratories in the optional genotypic characterisation component of the 
EQAS 
Test strain Expected gene Proportion of correct results (gene level) 
Proportion of correct 
results (variant level) 
Additional genes/variants 
identified 
S-10.3 
TEM-1 7/7 (100%) 5/5 (100%) 
CTX M-4 
CTX-M-9 9/9 (100%) 7/8 (88%) 
S-10.4 
TEM-1 6/6 (100%) 4/4 (100%) 
 
OXA-48 9/9 (100%) 9/9 (100%) 
S-10.7 
TEM-1 8/8 (100%) 6/6 (100%) 
CTX M-1 SHV-12 8/8 (100%) 6/6 (100%) 
CTX-M-15 9/9 (100%) 7/8 (88%) 
S-10.8 TEM-52 9/9 (100%) 8/8 (100%)  
 
4. Discussion 
It is important to consider that the number of 
EQAS participants differs from year to year, 
which implies that comparisons among different 
EQAS iterations should be interpreted with 
caution.  
As also specified in the EU regulation 
2013/652/EU, all participants in the present 
EQAS performed AST by dilution methods, 
primarily as microbroth determination.  
This 2015 proficiency test is the second 
possibility of testing Salmonella and 
Campylobacter strains with the panels designed 
to follow the requirements of Decision 
2013/652/EU. This allows for the possibility that 
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the experience obtained since the introduction 
of the legislation and the focus it has created on 
AST in the laboratories has had an impact on 
the generally satisfactory results obtained at the 
present EQAS. 
4.1 Salmonella trial  
Overall, the percentage of correct antimicrobial 
susceptibility test results of Salmonella was 
99.3%. All (n=31) participants obtained 
satisfactory results according to the level of 
acceptance (<5% deviation).  
As indicated in Figure 2, the overall quality of 
the results in the 2015-EQAS would appear to 
have increased again to the level of the years 
2012 and 2013, also, the measure when 
comparing results obtained from testing the 
internal control strain indicates a steady and 
very good quality of results.  
As indicated by Figure 3, all laboratories 
exhibited very good results with deviation levels 
below 5%. Follow-up has therefore not been 
necessary based on these results, and none of 
the laboratories were defined as outliers. 
For the E. coli reference strain, the obtained 
results were in general in agreement with the 
CLSI recommendations. Two laboratories (#4 
and #59) did not submit values related to the 
quality control strain, but within the submitted 
results, trimethoprim appeared to have most 
results outside the QC-range, and for cefepime 
one result was two steps above the QC-range.  
For the two laboratories #57 and #58 which had 
a deviation level for the AST results above the 
acceptance limit in EQAS 2014 with values of 
7.9% and 9.4%, respectively, one (#58) has this 
year increased their performance and have no 
deviations this year, and the other (#57) did not 
participate in the 2015-iteration.  
ESC-producing Salmonella test strains 
The detection of ESC-producing 
microorganisms remains to be important and is 
a mandatory part of this EQAS.  
Of the four Salmonella test strains relevant for 
this component of the EQAS (S-10.3, S-10.4, S-
10.7, and S-10.8), three were ESBL-
phenotypes and one was a carbapenemase 
phenotype. The testing and interpretation of 
results for these strains appeared not to cause 
major difficulties for any of the participating 
laboratories.  
Of the 31 laboratories which tested Salmonella, 
three laboratories (#39, #56 and #60) each 
submitted one incorrect AmpC-, ESBL-, 
carbapenemase categorization (App. 8a). The 
deviations all had background in the laboratory 
handling of the strains; for one, the incorrect 
categorization was based on an incorrect result 
as resistant for cefoxitin (#56; S-10.7). Even if 
no acceptance limit has been defined for this 
component of the EQAS, the overall result that 
98.8% of the obtained results were as expected 
appears satisfactory. 
4.2 Campylobacter trial  
For the Campylobacter component of this 
year’s EQAS, 31 laboratories submitted results 
leading to an overall percentage of correct AST 
results at 98.4%. The performance varied from 
no deviations up to 21.3% deviations, with 28 
laboratories performing satisfactorily according 
to the established acceptance range.  
It appears that there has been a decrease in 
the level of deviations for the overall AST result. 
Also, results obtained from testing the internal 
control strain indicate a steady and very good 
quality of results.  
Three laboratories (#36, #39, and #42) obtained 
deviation levels above 5%, one of these was 
defined as an outlier (#36) with a deviation level 
at 21.3%. For none of these laboratories, the 
values obtained for the QC-strain did not 
indicate methodical issues to be the reason for 
the obtained deviations.  
The EURL-AR have been in contact with all 
three laboratories presenting deviation levels 
above 5% to identify possible causes of this 
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unsatisfactory performance and to improve the 
quality of results. As for laboratory #36, the high 
level of deviations was caused by the switch of 
panels used and not switching to the 
corresponding result sheet for reading the 
plates. The laboratory transferred the obtained 
results to the correct result sheet and 
subsequently found that not all obtained results 
were as expected. As for laboratory #39, re-
testing of strain C-10.3 that caused five 
deviations was performed, leading this time to 
one deviation, only. The laboratory will continue 
follow-up when fresh stocks of the 
recommended panel for Campylobacter are 
received. At laboratory #42, the obtained MICs 
were as expected, but the deviations were 
caused by typos when submitting the 
interpretation into the database.  
All participating laboratories except two (#4 and 
#59) uploaded data from tests performed on the 
C. jejuni reference strain and the proportion of 
results within the QC intervals was 95.8%. Four 
of the six values outside the QC intervals were 
one step below or above the QC-limits, the 
remaining two were two dilution steps above or 
below the QC-limits. The laboratories obtaining 
these values should follow-up on these high/low 
values, and it is suggested that these values 
are monitored over time to ensure that the tests 
render a reliable result for the particular 
antimicrobial. 
Laboratories #29, and #40 which were regarded 
as outliers for the 2014 Campylobacter EQAS 
with deviation levels at 22.9% and 34.0%, 
respectively, both increased their performance 
extensively in the 2015-iteration and obtained 
deviation levels at 0.0%, and 2.1%, 
respectively.  
4.3 Genotypic characterisation 
The focus on genotypic characterization of 
microorganisms is increasing in the EU and 
worldwide. In EU, communication has been 
ongoing to improve laboratory detection and 
confirmation of ESBL- and AmpC-producing 
Enterobacteriaceae.  
Furthermore, the agenda now is focusing at the 
implementation of detection of carbapenemase 
resistant organisms and the importance of 
determining the identity of the genes 
responsible for the carbapenemase production 
by molecular methods.  
The optional genotypic characterisation offered 
as a supplementary part of this EQAS should 
therefore be seen as an important possibility for 
the NRL-AR’s to introduce this method in the 
laboratory and thereby be at the forefront when 
the method proposals are adopted. This year, 
nine laboratories participated in this optional 
EQAS component and even if no acceptance 
limit has been defined, the 98.3% correct 
results (N=119) appears to be a satisfactory 
results. 
5. Conclusions 
The goal of the EURL-AR EQAS is to have all 
participating NRLs performing antimicrobial 
susceptibility testing of Salmonella and 
Campylobacter with a deviation level below 5%. 
This seems within reach for Salmonella as well 
as for Campylobacter.  
Compared to the EQAS 2014, the performance 
of the NRL’s in 2015 appears to have improved 
for Salmonella AST’s (99.3% in 2015 and 
97.6% in 2014) and is now again at the level 
from 2013 and before (Figure 2). Regarding 
Campylobacter AST’s, the performance of the 
NRL’s also appear to have improved from 2014 
to 2015, with a change in deviation level from 
4.0% (2014) to 1.6% (2015). For the 
Campylobacter AST, one laboratory (#36) was 
regarded as an outlier. Follow-up/re-testing 
internally at the NRL’s with deviation levels 
above 5% has shown acceptable results for all 
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three laboratories (#36, #39, and #42).  
The test covering the identification of the 
phenotype of Salmonella test strains producing 
beta-lactamases of the ESBL-, AmpC, and 
carbapenemase-type rendered acceptable 
results. This is a priority area within the EURL-
AR activities, and it is encouraging to see 
acceptable results in identifying and 
categorizing these strains. 
Nine NRLs participated in the EQAS 
component consisting of genotypic testing of 
ESBL-, AmpC- and carbapenemase-producing 
Enterobacteriaceae presenting satisfactory 
results.  
Finally, the EURL-AR is open to suggestions to 
improve future EQAS trials and invites the 
entire network to contribute with ideas for 
training courses and specific focus areas to 
expand the network’s knowledge in 
antimicrobial resistance. 
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G00-06-001/01.12.2014 
EURL-AR EQAS pre-notification 
EQAS 2015 FOR SALMONELLA, CAMPYLOBACTER AND OPTIONAL GENOTYPIC 
CHARACTERISATION  
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable laboratory 
results of consistently good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight Salmonella isolates and eight 
Campylobacter isolates. Additionally, quality control (QC) strains E. coli ATCC 25922 (CCM 
3954) and C. jejuni ATCC 33560 (CCM 6214) will be distributed to new participants.  
This EQAS is specifically for NRL’s on antimicrobial resistance. Laboratories designated to be 
NRL-AR do not need to sign up to participate but are automatically regarded as participants. You 
may contact the EQAS-Coordinator if you wish to inform of changes in relation to your level of 
participation in previous years. The EURL-AR will be able to cover the expenses for one parcel per 
EU Member State. Therefore, countries with more than one laboratory registered on the EURL-AR 
contact-list will be contacted directly to confirm which laboratory will be included for participation 
free of charge.  
The invitation to participate in the proficiency test is extended to additional participants from 
official NRLs and participants from laboratories which are involved in the network but are not 
designated NRLs (cost for participation will be 100 EURO). 
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: Eight Salmonella strains, 
eight Campylobacter and for new participants also the QC strains mentioned above. Please provide 
the EQAS coordinator with documents or other information that can simplify customs procedures 
(e.g. specific text that should be written on the proforma invoice). To avoid delays, we kindly ask 
you to send this information already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in October 2015. The protocol for 
this proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than 
December 4th 2015 via the password-protected website.  
Appendix 1, page 1 of 2
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-
protected website once again to download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
Next EQAS: The next EURL-AR EQAS that we will send out to the EURL-AR network focuses on 
isolation of ESBL and ampC-producing E.coli from samples which is expected to be sent to 
participating laboratories around 1st November, 2015. 
Please contact me if you have comments or questions regarding the EQAS 
Sincerely, 
Susanne Karlsmose Pedersen (suska@food.dtu.dk) 
EQAS-Coordinator 
Appendix 1, page 2 of 2
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Participant list
Salmonella Campylobacter Genotypic characterisation Institute  Country
X X - Austrian Agency for Health and Food Safety Austria
X X X Institute of Public Health Belgium
X X - National Diagnostic and Research Veterinary Institute Bulgaria
X X - Croatian Veterinary Institut Croatia
X X - Veterinary Services Cyprus
X X X State Veterinary Institute Praha Czech Republic
X X - Danish Veterinary and Food Administration, DVFA Denmark
X X - Estonian Veterinary and Food Laboratory Estonia
X X - Finnish Food Safety Authority EVIRA Finland
X - - Agence nationale de sécurité sanitaire ANSES - Fougères LERMVD France
- X - Agence nationale de sécurité sanitaire ANSES - Ploufragan - LERAP France
X X X Federal Institute for Risk Assessment Germany
X X - Veterinary Laboratory of Chalkis Greece
X X - Central Agricultural Office Veterinary Diagnostic Directorate Hungary
X X - University of Iceland Iceland
X X - Central Veterinary Research Laboratory Ireland
X X X Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X - Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia
X X - National Food and Veterinary Risk Assessment Institute Lithuania
X X X Laboratoire national de Santé Luxembourg
X X - Public Health Laboratory Malta
X X X Central Veterinary Institute of Wageningen UR Netherlands
X X - Food and Consumer Product Safety Authority (VWA) Netherlands
X X X Veterinærinstituttet Norway
X X - National Veterinary Research Institute Poland
X X - Laboratorio National de Investigacáo Veterinaria Portugal
X X - Institute for Diagnosis and Animal Health Romania
X X - State Veterinary and Food Institute  (SVFI) Slovakia 
X X - National Veterinary Institute Slovenia
X X X Laboratorio Central de Sanidad, Animal de Algete Spain
X X - VISAVET Health Surveillance Center, Complutense University Spain
X X X National Veterinary Institute, SVA Sweden
X X - Vetsuisse Faculty Bern, Institute of Veterinary Bacteriology Switzerland
X X - The Veterinary Laboratory Agency United Kingdom
Designated NRL-AR by the compentent authority of the member state
Non-NRL-AR enrolled by the EURL-AR
Not a Member State of the EU
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Reference values (MIC-value and interpretation) - Salmonella 
Ampicillin Azithromycin Cefepime Cefotaxime Cefotaxime/clav F:F/C Cefoxitin Ceftazidime Ceftazidime/clav T:T/C Chloramphenicol Ciprofloxacin Colistin Ertapenem
AMP AZI FEP FOT F/C ratio FOX TAZ T/C ratio CHL CIP COL
EURL S-10.1  = 2 SUSC  = 8  <= 0.25 SUSC  <= 0.5 SUSC  <= 8 SUSC  = 0.06 SUSC  = 8 RESIST
EURL S-10.2  > 64 RESIST  = 8  <= 0.25 SUSC  <= 0.5 SUSC  > 128 RESIST  = 0.03 SUSC  <= 1 SUSC
EURL S-10.3  > 64 RESIST  = 8  = 2 = 8 RESIST  = 0.25/4  >=8  = 2 SUSC  = 1 SUSC  = 0.25/4  <8  <= 8 SUSC  = 0.5 RESIST  <= 1 SUSC  <= 0.015 SUSC
EURL S-10.4  > 64 RESIST  = 8 = 1  = 2 RESIST  = 2/4  <8  = 4 SUSC  <= 0.5 SUSC  = 0.5/4  <8  <= 8 SUSC  = 0.03 SUSC  <= 1 SUSC  = 2 RESIST
EURL S-10.5  > 64 RESIST  = 8  <= 0.25 SUSC  <= 0.5 SUSC  = 64 RESIST  = 0.03 SUSC  <= 1 SUSC
EURL S-10.6  = 2 SUSC  = 8  <= 0.25 SUSC  <= 0.5 SUSC  <= 8 SUSC  = 0.03 SUSC  <= 1 SUSC
EURL S-10.7  > 64 RESIST  > 64 > 32  > 64 RESIST  = 0.25/4  >=8  = 8 SUSC > 128 RESIST  = 2/4  >=8  > 128 RESIST  = 0.25 RESIST  <= 1 SUSC  = 0.03 SUSC
EURL S-10.8  > 64 RESIST  = 4  = 2  = 8 RESIST  = 0.06/4  >=8  = 2 SUSC = 16 RESIST  = 0.25/4  >=8  <= 8 SUSC  = 0.03 SUSC  = 2 SUSC  = 0.015 SUSC
Gentamicin IMIPENEM MEROPENEM Nalidixic acid Sulfamethoxazole TEMOCILLIN Tetracycline TIGECYCLINE Trimethoprim
GEN IMI MER NAL SMX TRM TETRA TGC TMP ESBL-category Relevant genes
EURL S-10.1  <= 0.5 SUSC  = 0.06 SUSC  <= 4 SUSC  = 32 SUSC  <= 2 SUSC  = 0.5 SUSC  <= 0.25 SUSC
EURL S-10.2  = 1 SUSC  = 0.06 SUSC  <= 4 SUSC  > 1024 RESIST  = 64 RESIST  = 0.5 SUSC  <= 0.25 SUSC
EURL S-10.3  = 1 SUSC = 0.5 SUSC  <= 0.03 SUSC  > 128 RESIST  = 32 SUSC  = 8  = 64 RESIST  = 0.5 SUSC  <= 0.25 SUSC
EURL S-10.4  <= 0.5 SUSC  = 4 RESIST  = 2 RESIST  <= 4 SUSC  = 32 SUSC > 128  <= 2 SUSC  = 0.5 SUSC  <= 0.25 SUSC
EURL S-10.5  <= 0.5 SUSC  = 0.06 SUSC  <= 4 SUSC  > 1024 RESIST  > 64 RESIST  = 2 RESIST  > 32 RESIST
EURL S-10.6  <= 0.5 SUSC  = 0.06 SUSC  <= 4 SUSC = 64 SUSC  = 4 SUSC  = 0.5 SUSC  <= 0.25 SUSC
EURL S-10.7  > 32 RESIST = 0.5 SUSC  = 0.06 SUSC = 8 SUSC  > 1024 RESIST  = 32  > 64 RESIST  = 1 SUSC  > 32 RESIST
EURL S-10.8  = 1 SUSC = 0.5 SUSC  = 0.06 SUSC  = 8 SUSC  = 32 SUSC  = 8  <= 2 SUSC  = 0.5 SUSC  = 0.5 SUSC
Resistant
TEM-1; CTX M-
15; SHV-12
TEM-52
N/A
N/A
Presumptive ESBL-phenotype
Presumptive ESBL-phenotype
N/A
N/A
Presumptive carbapenemase 
phenotype
Presumptive ESBL-phenotype TEM-1; CTX M-9
TEM-1; OXA-48
N/A
N/A
N/A
N/A
Appendix 3b, page 1 of 1Reference values (MIC-value and interpretation) - Campylobacter 
Ciprofloxacin Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
Species Code CIP ERY GEN NAL STR TET
C. jejuni EURL C-10.1  = 16 RESIST  > 128 RESIST  = 0.25 SUSC  > 64 RESIST  = 1 SUSC  <= 0.5 SUSC
C. coli EURL C-10.2  <= 0.12 SUSC  <= 1 SUSC  = 0.25 SUSC  = 4 SUSC  = 16 RESIST  <= 0.5 SUSC
C. jejuni EURL C-10.3  <= 0.12 SUSC  <= 1 SUSC  = 0.25 SUSC  = 2 SUSC  = 1 SUSC  <= 0.5 SUSC
C. coli EURL C-10.4  = 0.25 SUSC  > 128 RESIST  = 0.5 SUSC  = 8 SUSC  = 1 SUSC  = 2 SUSC
C. jejuni EURL C-10.5  = 8 RESIST  <= 1 SUSC  = 0.25 SUSC  > 64 RESIST  = 1 SUSC  > 64 RESIST
C. coli EURL C-10.6  > 16 RESIST  > 128 RESIST  = 0.5 SUSC  > 64 RESIST  = 2 SUSC  > 64 RESIST
C. coli EURL C-10.7  = 16 RESIST  <= 1 SUSC  = 0.5 SUSC  > 64 RESIST  = 4 SUSC  <= 0.5 SUSC
C. jejuni EURL C-10.8  = 16 RESIST  > 128 RESIST  > 16 RESIST  > 64 RESIST  > 16 RESIST  > 64 RESIST
Resistant
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G00-06-001/01.12.2014  
EURL-AR External Quality Assurance System 2015 
- Salmonella, Campylobacter and optional genotypic characterisation 
 
Id: «Lab_no_» 
«Name» 
«Institute__»  
«Country» 
Kgs. Lyngby, October 2015 
Dear «Name», 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2015. Upon arrival to your 
laboratory, the strains should be stored dark and at 4C for stabs, and dark and cool for lyophilized 
strains. Charcoal swabs must be subcultured straight away.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-AR 
EQAS are available: 
- Protocol for Salmonella and Campylobacter including test forms 
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains 
 
We ask you to examine the eight Salmonella and the eight Campylobacter strains that we send to 
you by performing antimicrobial susceptibility testing. The ESBL-producing Salmonella strains 
should be characterised genotypically (optional) according to the description in the protocol. In the 
protocol you can find detailed description of the procedures to follow. Additionally, you can find a 
description of the procedure to enter your results into the interactive web database. For accessing 
the database, you need this username and password. 
 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
 
Results should be submitted to the database no later than December 4th 2015.  
 
Please acknowledge receipt of this parcel immediately upon arrival (to suska@food.dtu.dk).  
Do not hesitate to contact us for further information. 
 
Yours sincerely, 
 
Susanne Karlsmose Pedersen 
EQAS-Coordinator 
 
EU Reference Laboratory for Antimicrobial Resistance 
External Quality Assurance System (EQAS) 2015 
PROTOCOL 
For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional 
genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 
1 INTRODUCTION ...................................................................................................................  1 
2 OBJECTIVES  .......................................................................................................................... 2 
3 OUTLINE OF THE SALM/CAMP EQAS 2015  .................................................................. 2 
3.1    Shipping, receipt and storage of strains  ........................................................................ 2 
3.2 QC reference strains ...................................................................................................... 2 
3.3 Antimicrobial susceptibility testing  .............................................................................. 3 
3.4 Optional genotypic characterisation ............................................................................. 6 
4 REPORTING OF RESULTS AND EVALUATION  ........................................................... 6 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE  ............................. 7 
1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of Salmonella and Campylobacter is among the tasks of 
the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR). The Salm/Camp EQAS 
2015 will include AST of eight Salmonella and Campylobacter strains and AST of reference strains 
E. coli ATCC 25922 (CCM 3954) and C. jejuni ATCC 33560 (CCM 6214).
The above-mentioned reference strains are included in the parcel only for new participants of the 
EQAS who did not receive them previously. The reference strains are original CERTIFIED cultures 
provided free of charge, and should be used for future internal quality control for antimicrobial 
susceptibility testing in your laboratory. The reference strains will not be included in the years to 
come. Therefore, please take proper care of these strains. Handle and maintain them as suggested in 
the manual ‘Subculture and Maintenance of QC Strains’ available on the EURL-AR website (see 
www.eurl-ar.eu).  
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Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
2 OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to Salmonella and 
Campylobacter. Further objectives are to evaluate and improve the comparability of surveillance 
data on antimicrobial susceptibility of Salmonella and Campylobacter reported to EFSA by 
different laboratories. 
3 OUTLINE OF THE SALM/CAMP EQAS 2015 
3.1    Shipping, receipt and storage of strains 
In October 2015, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight Salmonella and Campylobacter strains from the National Food 
Institute. This parcel will also contain reference strains, but only for participants who did not 
receive them previously. All strains belong to UN3373, Biological substance, category B. Extended 
spectrum beta-lactamase (ESBL)-producing strains as well as carbapenemase producing strains are 
included in the selected material and are part of the optional EQAS-item, consisting of 
characterization of genes conferring ESBL- or carbapenemase production.  
The reference strains are shipped lyophilised, the Campylobacter test strains are shipped as a 
charcoal swabs and the Salmonella test strains are stab cultures. On arrival, the stab cultures and the 
charcoal swabs must be subcultured, and all cultures should be adequately stored until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below. 
3.2 QC reference strains  
For a suggested procedure for reconstitution of the lyophilised, please refer to the document 
‘Instructions for opening and reviving lyophilised cultures’ on the EURL-AR-website (see 
www.eurl-ar.eu). 
Note that, for the testing of the E. coli ATCC25922 reference strain, the two compounds, 
sulfamethoxazole and sulfisoxazole, are regarded as comparable, i.e. the obtained MIC-value from 
the testing of sulfamethoxazole will be evaluated against the acceptance range listed in CLSI M100 
for sulfisoxazole. 
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3.4 Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in Tables 1, 2 and 3, using 
the method implemented in your laboratory for performing monitoring for EFSA and applying the 
interpretative criteria listed below. 
Participants should perform minimum inhibitory concentration (MIC) determination using the 
methods stated in the EC regulation EC 652/2013. For interpretation of the results, use the cut-off 
values listed in Tables 1, 2 and 3 (except where indicated) represent the current epidemiological 
cut-off values developed by EUCAST (www.eucast.org), and allow categorisation of bacterial 
isolates into two categories; resistant or susceptible. A categorisation as intermediate is not 
accepted.  
As the current regulation and recommendations focus on MIC testing only, results obtained by disk 
diffusion cannot be submitted. 
3.4.1 Salmonella. 
The interpretative criteria that should be applied for categorizing the Salmonella test strain as 
resistant or susceptible are those listed in Tables 1 and 2.  
Table 1: Antimicrobials recommended for AST of Salmonella spp. and interpretative criteria according to 
table 1 in EC regulation 652/2013 
Antimicrobial MIC (µg/mL) (R>) 
Ampicillin (AMP) 8 
Azithromycin (AZI) Not available* 
Cefotaxime (FOT) 0.5 
Ceftazidime (TAZ) 2 
Chloramphenicol (CHL) 16 
Ciprofloxacin (CIP) 0.06 
Colistin (COL) 2 
Gentamicin (GEN) 2 
Meropenem (MERO) 0.125 
Nalidixic acid (NAL) 16 
Sulfonamides (SMX) 256** 
Tetracycline (TET) 8 
Tigecycline (TGC) 1*** 
Trimethoprim (TMP) 2 
* Participants are requested to upload the MIC value obtained without selecting an interpretation.  
** CLSI M100 Table 2A 
*** Data from EUCAST is available for S. Enteritidis, S. Typhimurium, S. Typhi and S. Paratyphi (for the 
purpose of this proficiency test, the ECOFF at 1 is applied) 
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Table 2: Antimicrobials recommended for additional AST of Salmonella spp. resistant to cefotaxime, 
ceftazidime or meropenem and interpretative criteria according to table 4 in EC regulation 652/2013 
Antimicrobial MIC (µg/mL) (R>) 
Cefepime, FEP Not available* 
Cefotaxime, FOT 0.5 
Cefotaxime + clavulanic acid (F/C) Not applicable 
Cefoxitin, FOX 8 
Ceftazidime, TAZ 2 
Ceftazidime+ clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.06 
Imipenem, IMI 1 
Meropenem, MERO 0.125 
Temocillin, TRM Not available* 
* Participants are requested to upload the MIC value obtained without selecting an interpretation 
 
Plasmid-mediated quinolone resistance  
When performing antimicrobial susceptibility testing of the Salmonella test strains, the 
interpretative criteria listed in Table 1 should be able to detect plasmid mediated quinolone resistant 
test strains.  
Extended-beta-lactam- and carbapenem resistance  
Confirmatory tests for AmpC-, ESBL- and carbapenemase production are mandatory on all strains 
resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem and should be performed by 
testing the second panel of antimicrobials (Table 2 in this document corresponding to Table 4 in EC 
regulation 652/2013). 
Confirmatory tests for AmpC-, ESBL- and carbapenemase production require the use of both 
cefotaxime (FOT) and ceftazidime (TAZ) alone and in combination with a β-lactamase inhibitor 
(clavulanic acid). Synergy is defined either as a ≥ 3 twofold concentration decrease in an MIC for 
either antimicrobial agent tested in combination with clavulanic acid vs. its MIC when tested alone 
(MIC FOT : FOT/Cl or TAZ : TAZ/Cl ratio ≥ 8) (CLSI M100 Table 2A; Enterobacteriaceae). The 
presence of synergy indicates ESBL production. Resistance to cefepime gives further indication of 
ESBL production, but is not essential. Confirmatory test for carbapenemase production requires the 
testing of meropenem (MERO).  
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase that may be verified by PCR and sequencing.  
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The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EFSA 20121) indicating the strains as:  
• Presumptive ESBL: strains with positive synergy test, susceptible to cefoxitin and 
resistant to cefepime  
• Presumptive ESBL+pAmpC: strains with positive or negative synergy test, resistant to 
cefoxitin and resistant to cefepime  
• Presumptive pAmpC phenotype: strains with negative synergy test, resistant to cefoxitin 
and susceptible to cefepime 
• Presumptive carbapenemase phenotype: strain resistant to meropenem  
• Unusual phenotype: any other combinations  
We recommend, however, that strains showing synergy with clavulanic acid for at least one of the 
third generation cephalosporins (cefotaxime or ceftazidime) should be considered ESBL-producing, 
independently of the cefepime result. 
3.4.2 Campylobacter   
For AST of Campylobacter, MIC methods should be applied, i.e. broth or agar dilution methods 
using incubation at 36-37ºC for 48 hours or 42ºC for 24 hours.  
Table 3: Antimicrobials recommended for AST of Campylobacter jejuni and C. coli and 
interpretative criteria according to table 1 in EC regulation 652/2013 
Antimicrobial C. jejuni C. coli 
MIC (µg/mL) (R>) MIC (µg/mL) (R>) 
Ciprofloxacin (CIP) 0.5 0.5 
Erythromycin (ERY) 4 8 
Gentamicin (GEN) 2 2 
Nalidixic acid (NAL) 16 16 
Streptomycin (STR) 4 4 
Tetracycline (TET) 1 2 
 
 
Identification of Campylobacter species 
Species identification of the Campylobacter test strains must be performed by the NRLs using in-
house methods or adopting the protocol available on the EURL-AR website under: http://eurl-
ar.eu/233-protocols.htm. 
1 European Food Safety Authority; Technical specifications on the harmonised monitoring and reporting of 
antimicrobial resistance in Salmonella, Campylobacter and indicator Escherichia coli and Enterococcus spp. bacteria 
transmitted through food. EFSA Journal 2012; 10(6):2742. [64 pp.] doi:10.2903/j.efsa.2012.2742. Available online:  
www.efsa.europa.eu/efsajournal  
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3.5 Optional genotypic characterisation 
For the optional genotypic characterisation of the AmpC-, ESBL- or carbepenemase producing 
Salmonella test strains, the requested results are the genes conferring AmpC-, ESBL- or 
carbepenemase -production harboured in the test strains. The genes included in the test are the 
following: ACC, ACT, CMY, CTX, DHA, FOX, GES, IMP, KPC, MOX, NDM, OXA, PER, SHV, 
TEM, VEB, and VIM. The database lists the relevant variants of the genes.   
When uploading the results in the database, the identified genes will be evaluated against the 
expected results. The results will be evaluated on the detected gene (ACC-, ACT-, CMY-, etc.) as 
well as the variant identified.  
The method used for the genotypic characterisation should be your laboratory’s routine method. 
The expected results listed in the database are those obtained by the EURL-AR.  
4 REPORTING OF RESULTS AND EVALUATION 
Test forms are available for recording your results before you enter them into the interactive web 
database.  
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than December 4th 2015. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
 
Susanne Karlsmose Pedersen 
National Food Institute,  
Technical University of Denmark 
Søltofts Plads, Building 221, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
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5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms. 
Enter the EURL-AR EQAS 2015 start web page (http://eurl-ar.food.dtu.dk), write your username 
and password (lower-case) and press enter. Your username and password are indicated in the letter 
following your strains. Do not hesitate to contact us if you experience problems with the login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
inputs before. 
Click on either “Salmonella test results” or “Campylobacter test results” for input of test results. 
Click on "Start of Data Entry - Methods” 
In the next page, you navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing and the brand 
of MIC trays, etc.  
When submitting Campylobacter results, fill in the incubation conditions applied for susceptibility 
testing of Campylobacter – 36°C/48h or 42°C/24h. 
Click on "save and go to next page” 
In the data entry pages, you enter the species (for Campylobacter only), the obtained MIC-value 
and the interpretation (R, resistant or S, susceptible) for each Salmonella and Campylobacter strain. 
For Salmonella, remember to also report the results for the ESBL detection tests. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains, please enter MIC values in µg/ml. Remember to use 
the operator keys to show symbols like “equal to”, etc. 
Click on “save“. 
Review the input pages by browsing through them and make corrections if necessary. Remember to 
save a page if you make corrections. If you press home a page without saving changes, you will see 
an error screen. In this case, click on “save“ to save your results, browse back to the page and then 
continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields as  YOU 
CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database. 
If you have performed the optional genotypic characterisation: 
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Click on “Gene test” and follow the description in the database for upload of the results of the 
optional genotypic characterization. Approve your input. Be sure that you have filled in all the 
results before approval. The approval blocks your data entry in the interactive database, but allows 
you to see the submitted results. 
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Salmonella, Campylobacter and genetic characterisation 
 
TEST FORMS 
   
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
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TEST FORM                                                            
 
Does your laboratory have an accreditation for performing Salmonella AST?   Yes     No 
 
Which method did you use for antimicrobial susceptibility testing of Salmonella in this EQAS: 
  Broth microdilution    
  Agar dilution 
 
 Brand of microbroth plates/agar:        
 Incubation conditions:      °C/     h 
 
How many Salmonella isolates does your laboratory annually isolate:       
 
How many Salmonella isolates does your laboratory annually test for antimicrobial susceptibility by 
a MIC method:       
 
Which method was followed for the preparation of the inoculum (please describe) 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORM          
 
Does your laboratory have an accreditation for Campylobacter AST?  Yes     No 
 
 
Incubation conditions:     36-37ºC / 48h   42ºC / 24h 
 
Method used for antimicrobial susceptibility testing of Campylobacter in this EQAS:: 
 Broth microdilution 
 Agardilution 
 
Brand of microbroth plates/agar:       
 
How many Campylobacter isolates does your laboratory annually isolate:       
How many Campylobacter isolates does your laboratory annually susceptibility test:       
 
Which method was followed for the preparation of the inoculum (please describe) 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 10.X 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 10.X 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
 Presumptive ESBL 
 Presumptive ESBL+ pAmpC 
 Presumptive pAmpC 
 Presumptive carbapenemase 
 
 Unusual phenotype 
 No ESBL, AmpC- or carbapenemase 
 
Comments (include optional genotype or other results):       
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TEST FORM                                                            
 
Antimicrobial susceptibility testing of reference strain E. coli ATCC 25922 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
1st panel 
 
 
Ampicillin, AMP        
Azithromycin, AZI       
Cefotaxime, FOT       
Ceftazidime, TAZ       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Colistin, COL       
Gentamicin, GEN       
Meropenem, MERO       
Nalidixic acid, NAL       
Sulfamethoxazole, SMX*       
Tetracycline, TET       
Tigecycline, TGC       
Trimethoprim, TMP       
2nd panel Cefepime, FEP       
Cefotaxime, FOT       
Cefotaxime + clavulanic acid (F/C)       
Cefoxitin, FOX       
Ceftazidime, TAZ       
Ceftazidime+ clavulanic acid (T/C)       
Ertapenem, ETP       
Imipenem, IMI       
Meropenem, MERO       
Temocillin, TRM       
* for the testing of the E. coli ATCC25922 reference strain, sulfamethoxazole and sulfisoxazole, are 
regarded as comparable, i.e. the obtained MIC-value from the testing of sulfamethoxazole will be evaluated 
against the acceptance range listed in CLSI M100 for sulfisoxazole (CLSI M100, Table 3). 
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TEST FORM                                                           
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C-10.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-10.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-10.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-10.X 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic acid             
Streptomycin             
Tetracycline             
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TEST FORM                                                           
 
Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
36 °C/48 hours 
 
42 °C/24 hours 
 
 
C. jejuni ATCC 33560 
 
Ciprofloxacin             
Erythromycin             
Nalidixic acid             
Tetracycline             
 
 
  
For Agar dilution: 
 
 Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
 
C. jejuni ATCC 33560 
 
 
Ciprofloxacin       
Erythromycin        
Gentamicin       
Nalidixic acid        
Tetracycline       
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TEST FORM – genotypic characterisation                                    
 
Genotypic characterisation of the test strains 
 
Strain code:  
      
Method used:        
If PCR-methods, additional information should be given below 
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Comments:       
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
Instructions adjusted from Czech Collection of Microorganisms (CCM) document ’Instructions for 
Opening and Reviving of Freeze-Dried Bacteria and Fungi’ available on http://www.sci.muni.cz.  
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule
b. Make a file cut on the ampoule near the middle of the plug (see Figure 1)
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from
just below the plug to the pointed end
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into
the ampoule
e. Remove the pointed end of the ampoule into disinfectant
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable
solid and /or liquid media
g. Incubate the inoculated medium at appropriate conditions for several days
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of
the original ampoule before discarding
Notes:  
 Cultures should be grown on media and under conditions as recommended in the CCM
catalogue (see http://www.sci.muni.cz)
 Cultures may need at least one subculturing before they can be optimally used in experiments
 Unopened ampoules should be kept in a dark and cool place!
Figure 1: from CCM document ’Instructions for Opening 
and Reviving of Freeze-Dried Bacteria and Fungi’ available 
on http://www.sci.muni.cz 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S24, January 2014 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A9, January 2012 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination.
 Obtain QC strains from a reliable source such as ATCC
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC
validation)
 Any changes in materials or procedure must be validated with QC before implemented
 For example: Agar and broth methods may give different QC ranges for drugs such as
glycopeptides, aminoglycosides and macrolides
 Periodically perform colony counts to check the inoculum preparation procedure
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 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing.  
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DAILY MIC QC CHART 
 
  Reference: CLSI M7-A9, page 46 
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Quality Control ranges for ATCC reference strains
Antimicrobial Microbroth                (36-37°C/48h)
Microbroth 
(42°C/24h)
Agar dilution     
(36-37°C/48h)
Agar dilution     
(42°C/24h)
Ciprofloxacin, CIP 0.06-0.25 0.03-0.12 0.12-1 0.06-0.5
Erythromycin, ERY 0.5-2 0.25-2 1-8 1-4
Gentamicin, GEN 0.5-2 0.25-2 0.5-2 0.5-4
Nalidixic acid, NAL 4-16 4-16 None None
Tetracycline, TET 0.25-2 0.25-1 None None
E. coli ATCC 25922
Antimicrobial MIC
Ampicillin, AMP 2-8
Azithromycin, AZT none
Cefepime, FEP 0.015-0.12
Cefotaxime, FOT 0.03-0.12
Cefotaxime + clavulanic acid, F/C none
Cefoxitin, FOX 2-8
Ceftazidime, CAZ 0.06-0.5
Ceftazidime + clavulanic acid, T/C none
Chloramphenicol, CHL 2-8
Ciprofloxacin, CIP 0.004-0.016
Colistin, COL 0.25-2
Ertapenem, ETP 0.004-0.016
Gentamicin, GEN 0.25-1
Imipenem, IMI 0.06-0.25
Meropenem, MERO 0.008-0.06
Nalidixic acid, NAL 1-4
Sulfisoxazole, FIS 8-32
Temocillin, TRM none
Tetracycline, TET 0.5-2
Campylobacter jejuni ATCC 33560
MIC ranges (µg/mL)  are according to CLSI (VET01-S2) 
Tigecycline, TGC 0.03-0.25
Trimethoprim, TMP 0.5-2
MIC ranges (µg/mL) are according to CLSI M100 S25 (range for ciprofloxacin and ertapenem 
extended to include 0.016).
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Test results from the reference strain E. coli ATCC 25922
Lab no. Panel Antimicrobial Operator Value Low limit High limit Mark Method
2 1 Ampicillin = 4 2 8 1 MIC
2 1 Azithromycin = 4 - - - MIC
2 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
2 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
2 1 Chloramphenicol <= 8 2 8 1 MIC
2 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
2 1 Colistin <= 1  0.25 2 1 MIC
2 1 Gentamicin <=  0.5  0.25 1 1 MIC
2 1 Meropenem <=  0.03  0.008  0.06 1 MIC
2 1 Nalidixic acid <= 4 1 4 1 MIC
2 1 Sulfamethoxazole = 16 8 32 1 MIC
2 1 Tetracycline <= 2  0.5 2 1 MIC
2 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
2 1 Trimethoprim =  0.5  0.5 2 1 MIC
6 1 Ampicillin = 4 2 8 1 MIC
6 1 Azithromycin = 4 - - - MIC
6 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
6 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
6 1 Chloramphenicol <= 8 2 8 1 MIC
6 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
6 1 Colistin <= 1  0.25 2 1 MIC
6 1 Gentamicin <=  0.5  0.25 1 1 MIC
6 1 Meropenem <=  0.03  0.008  0.06 1 MIC
6 1 Nalidixic acid <= 4 1 4 1 MIC
6 1 Sulfamethoxazole = 32 8 32 1 MIC
6 1 Tetracycline <= 2  0.5 2 1 MIC
6 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
6 1 Trimethoprim = 1  0.5 2 1 MIC
6 2 Cefepime <=  0.06  0.015  0.125 1 MIC
6 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
6 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
6 2 Cefoxitin = 4 2 8 1 MIC
6 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
6 2 Ceftazidime/clavulanic acid <=  0.12 - - - MIC
6 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
6 2 Imipenem =  0.25  0.06  0.25 1 MIC
6 2 Meropenem <=  0.03  0.008  0.06 1 MIC
6 2 Temocillin = 4 - - - MIC
9 1 Ampicillin = 4 2 8 1 MIC
9 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
9 1 Chloramphenicol = 8 2 8 1 MIC
9 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
9 1 Colistin <= 1  0.25 2 1 MIC
9 1 Gentamicin <=  0.5  0.25 1 1 MIC
9 1 Meropenem <=  0.03  0.008  0.06 1 MIC
9 1 Nalidixic acid <= 4 1 4 1 MIC
9 1 Sulfamethoxazole = 16 8 32 1 MIC
9 1 Tetracycline <= 2  0.5 2 1 MIC
9 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
9 1 Trimethoprim = 1  0.5 2 1 MIC
9 2 Cefepime <=  0.06  0.015  0.125 1 MIC
9 2 Cefoxitin = 4 2 8 1 MIC
9 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
9 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
9 2 Imipenem <=  0.12  0.06  0.25 1 MIC
9 2 Meropenem <=  0.03  0.008  0.06 1 MIC
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11 1 Ampicillin = 4 2 8 1 MIC
11 1 Azithromycin = 8 - - - MIC
11 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
11 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
11 1 Chloramphenicol <= 8 2 8 1 MIC
11 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
11 1 Colistin <= 1  0.25 2 1 MIC
11 1 Gentamicin = 1  0.25 1 1 MIC
11 1 Meropenem <=  0.03  0.008  0.06 1 MIC
11 1 Nalidixic acid <= 4 1 4 1 MIC
11 1 Sulfamethoxazole = 32 8 32 1 MIC
11 1 Tetracycline <= 2  0.5 2 1 MIC
11 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
11 1 Trimethoprim =  0.5  0.5 2 1 MIC
11 2 Cefepime <=  0.06  0.015  0.125 1 MIC
11 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
11 2 Cefotaxime/clavulanic acid <=  0.12 - - - MIC
11 2 Cefoxitin = 4 2 8 1 MIC
11 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
11 2 Ceftazidime/clavulanic acid =  0.25 - - - MIC
11 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
11 2 Imipenem <=  0.12  0.06  0.25 1 MIC
11 2 Meropenem <=  0.03  0.008  0.06 1 MIC
11 2 Temocillin = 32 - - - MIC
12 1 Ampicillin = 8 2 8 1 MIC
12 1 Azithromycin = 4 - - - MIC
12 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
12 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
12 1 Chloramphenicol <= 8 2 8 1 MIC
12 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
12 1 Colistin <= 1  0.25 2 1 MIC
12 1 Gentamicin = 1  0.25 1 1 MIC
12 1 Meropenem <=  0.03  0.008  0.06 1 MIC
12 1 Nalidixic acid <= 4 1 4 1 MIC
12 1 Sulfamethoxazole = 16 8 32 1 MIC
12 1 Tetracycline <= 2  0.5 2 1 MIC
12 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
12 1 Trimethoprim =  0.5  0.5 2 1 MIC
12 2 Cefepime <=  0.06  0.015  0.125 1 MIC
12 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
12 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
12 2 Cefoxitin = 4 2 8 1 MIC
12 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
12 2 Ceftazidime/clavulanic acid =  0.25 - - - MIC
12 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
12 2 Imipenem <=  0.12  0.06  0.25 1 MIC
12 2 Meropenem <=  0.03  0.008  0.06 1 MIC
12 2 Temocillin = 16 - - - MIC
16 1 Ampicillin = 4 2 8 1 MIC
16 1 Azithromycin = 4 - - - MIC
16 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
16 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
16 1 Chloramphenicol <= 8 2 8 1 MIC
16 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
16 1 Colistin <= 1  0.25 2 1 MIC
16 1 Gentamicin <=  0.5  0.25 1 1 MIC
16 1 Meropenem <=  0.03  0.008  0.06 1 MIC
16 1 Nalidixic acid <= 4 1 4 1 MIC
16 1 Sulfamethoxazole = 32 8 32 1 MIC
16 1 Tetracycline <= 2  0.5 2 1 MIC
16 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
16 1 Trimethoprim =  0.5  0.5 2 1 MIC
16 2 Cefepime <=  0.06  0.015  0.125 1 MIC
16 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
16 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
16 2 Cefoxitin = 4 2 8 1 MIC
16 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
16 2 Ceftazidime/clavulanic acid =  0.25 - - - MIC
16 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
16 2 Imipenem <=  0.12  0.06  0.25 1 MIC
16 2 Meropenem <=  0.03  0.008  0.06 1 MIC
16 2 Temocillin = 16 - - - MIC
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17 1 Ampicillin = 8 2 8 1 MIC
17 1 Azithromycin = 4 - - - MIC
17 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
17 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
17 1 Chloramphenicol <= 8 2 8 1 MIC
17 1 Ciprofloxacin <=  0.01  0.004  0.016 1 MIC
17 1 Colistin <= 1  0.25 2 1 MIC
17 1 Gentamicin = 1  0.25 1 1 MIC
17 1 Meropenem <=  0.03  0.008  0.06 1 MIC
17 1 Nalidixic acid <= 4 1 4 1 MIC
17 1 Sulfamethoxazole = 32 8 32 1 MIC
17 1 Tetracycline <= 2  0.5 2 1 MIC
17 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
17 1 Trimethoprim =  0.5  0.5 2 1 MIC
17 2 Cefepime <=  0.06  0.015  0.125 1 MIC
17 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
17 2 Cefotaxime/clavulanic acid =  0.12 - - - MIC
17 2 Cefoxitin = 4 2 8 1 MIC
17 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
17 2 Ceftazidime/clavulanic acid =  0.25 - - - MIC
17 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
17 2 Imipenem =  0.25  0.06  0.25 1 MIC
17 2 Meropenem <=  0.03  0.008  0.06 1 MIC
17 2 Temocillin = 16 - - - MIC
18 1 Ampicillin = 2 2 8 1 MIC
18 1 Azithromycin <= 2 - - - MIC
18 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
18 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
18 1 Chloramphenicol <= 8 2 8 1 MIC
18 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
18 1 Colistin <= 1  0.25 2 1 MIC
18 1 Gentamicin <=  0.5  0.25 1 1 MIC
18 1 Meropenem <=  0.03  0.008  0.06 1 MIC
18 1 Nalidixic acid <= 4 1 4 1 MIC
18 1 Sulfamethoxazole = 32 8 32 1 MIC
18 1 Tetracycline <= 2  0.5 2 1 MIC
18 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
18 1 Trimethoprim = 1  0.5 2 1 MIC
18 2 Cefepime =  0.12  0.015  0.125 1 MIC
18 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
18 2 Cefoxitin = 4 2 8 1 MIC
18 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
18 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
18 2 Imipenem <=  0.12  0.06  0.25 1 MIC
18 2 Meropenem <=  0.03  0.008  0.06 1 MIC
18 2 Temocillin = 8 - - - MIC
19 1 Ampicillin = 4 2 8 1 MIC
19 1 Azithromycin = 4 - - - MIC
19 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
19 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
19 1 Chloramphenicol <= 8 2 8 1 MIC
19 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
19 1 Colistin <= 1  0.25 2 1 MIC
19 1 Gentamicin <=  0.5  0.25 1 1 MIC
19 1 Meropenem <=  0.03  0.008  0.06 1 MIC
19 1 Nalidixic acid <= 4 1 4 1 MIC
19 1 Sulfamethoxazole = 32 8 32 1 MIC
19 1 Tetracycline <= 2  0.5 2 1 MIC
19 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
19 1 Trimethoprim = 5  0.5 2 0 MIC
19 2 Cefepime <=  0.06  0.015  0.125 1 MIC
19 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
19 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
19 2 Cefoxitin = 4 2 8 1 MIC
19 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
19 2 Ceftazidime/clavulanic acid <=  0.12 - - - MIC
19 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
19 2 Imipenem <=  0.12  0.06  0.25 1 MIC
19 2 Meropenem <=  0.03  0.008  0.06 1 MIC
19 2 Temocillin = 8 - - - MIC
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20 1 Ampicillin = 4 2 8 1 MIC
20 1 Azithromycin = 8 - - - MIC
20 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
20 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
20 1 Chloramphenicol <= 8 2 8 1 MIC
20 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
20 1 Colistin <= 1  0.25 2 1 MIC
20 1 Gentamicin <=  0.5  0.25 1 1 MIC
20 1 Meropenem <=  0.03  0.008  0.06 1 MIC
20 1 Nalidixic acid <= 4 1 4 1 MIC
20 1 Sulfamethoxazole = 32 8 32 1 MIC
20 1 Tetracycline <= 2  0.5 2 1 MIC
20 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
20 1 Trimethoprim =  0.5  0.5 2 1 MIC
20 2 Cefepime <=  0.06  0.015  0.125 1 MIC
20 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
20 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
20 2 Cefoxitin = 2 2 8 1 MIC
20 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
20 2 Ceftazidime/clavulanic acid =  0.25 - - - MIC
20 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
20 2 Imipenem <=  0.12  0.06  0.25 1 MIC
20 2 Meropenem <=  0.03  0.008  0.06 1 MIC
20 2 Temocillin = 8 - - - MIC
21 1 Ampicillin = 4 2 8 1 MIC
21 1 Azithromycin = 4 - - - MIC
21 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
21 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
21 1 Chloramphenicol <= 8 2 8 1 MIC
21 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
21 1 Colistin <= 1  0.25 2 1 MIC
21 1 Gentamicin <=  0.5  0.25 1 1 MIC
21 1 Meropenem <=  0.03  0.008  0.06 1 MIC
21 1 Nalidixic acid <= 4 1 4 1 MIC
21 1 Sulfamethoxazole = 32 8 32 1 MIC
21 1 Tetracycline <= 2  0.5 2 1 MIC
21 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
21 1 Trimethoprim =  0.5  0.5 2 1 MIC
21 2 Cefepime =  0.5  0.015  0.125 0 MIC
21 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
21 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
21 2 Cefoxitin = 8 2 8 1 MIC
21 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
21 2 Ceftazidime/clavulanic acid =  0.25 - - - MIC
21 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
21 2 Imipenem <=  0.12  0.06  0.25 1 MIC
21 2 Meropenem <=  0.03  0.008  0.06 1 MIC
21 2 Temocillin = 16 - - - MIC
22 1 Ampicillin = 2 2 8 1 MIC
22 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
22 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
22 1 Chloramphenicol <= 8 2 8 1 MIC
22 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
22 1 Colistin <= 1  0.25 2 1 MIC
22 1 Gentamicin <=  0.5  0.25 1 1 MIC
22 1 Meropenem <=  0.03  0.008  0.06 1 MIC
22 1 Nalidixic acid <= 4 1 4 1 MIC
22 1 Tetracycline <= 2  0.5 2 1 MIC
22 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
22 1 Trimethoprim =  0.5  0.5 2 1 MIC
22 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
22 2 Cefoxitin = 4 2 8 1 MIC
22 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
22 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
22 2 Imipenem <=  0.12  0.06  0.25 1 MIC
22 2 Meropenem <=  0.03  0.008  0.06 1 MIC
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23 1 Ampicillin = 4 2 8 1 MIC
23 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
23 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
23 1 Chloramphenicol <= 8 2 8 1 MIC
23 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
23 1 Colistin <= 1  0.25 2 1 MIC
23 1 Gentamicin = 1  0.25 1 1 MIC
23 1 Meropenem <=  0.03  0.008  0.06 1 MIC
23 1 Nalidixic acid <= 4 1 4 1 MIC
23 1 Sulfamethoxazole = 16 8 32 1 MIC
23 1 Tetracycline <= 2  0.5 2 1 MIC
23 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
23 1 Trimethoprim =  0.5  0.5 2 1 MIC
23 2 Cefepime <=  0.06  0.015  0.125 1 MIC
23 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
23 2 Cefoxitin = 2 2 8 1 MIC
23 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
23 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
23 2 Imipenem <=  0.12  0.06  0.25 1 MIC
23 2 Meropenem <=  0.03  0.008  0.06 1 MIC
25 1 Ampicillin = 4 2 8 1 MIC
25 1 Azithromycin = 4 - - - MIC
25 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
25 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
25 1 Chloramphenicol <= 8 2 8 1 MIC
25 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
25 1 Colistin <= 1  0.25 2 1 MIC
25 1 Gentamicin <=  0.5  0.25 1 1 MIC
25 1 Meropenem <=  0.03  0.008  0.06 1 MIC
25 1 Nalidixic acid <= 4 1 4 1 MIC
25 1 Sulfamethoxazole <= 8 8 32 1 MIC
25 1 Tetracycline <= 2  0.5 2 1 MIC
25 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
25 1 Trimethoprim =  0.5  0.5 2 1 MIC
26 1 Ampicillin = 4 2 8 1 MIC
26 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
26 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
26 1 Chloramphenicol <= 8 2 8 1 MIC
26 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
26 1 Colistin <= 1  0.25 2 1 MIC
26 1 Gentamicin = 1  0.25 1 1 MIC
26 1 Meropenem <=  0.03  0.008  0.06 1 MIC
26 1 Nalidixic acid <= 4 1 4 1 MIC
26 1 Sulfamethoxazole = 16 8 32 1 MIC
26 1 Tetracycline <= 2  0.5 2 1 MIC
26 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
26 1 Trimethoprim =  0.5  0.5 2 1 MIC
29 1 Ampicillin = 8 2 8 1 MIC
29 1 Chloramphenicol = 8 2 8 1 MIC
29 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
29 1 Colistin = 1  0.25 2 1 MIC
29 1 Gentamicin =  0.5  0.25 1 1 MIC
29 1 Nalidixic acid <= 4 1 4 1 MIC
29 1 Sulfamethoxazole = 16 8 32 1 MIC
29 1 Tetracycline = 2  0.5 2 1 MIC
29 1 Trimethoprim = 1  0.5 2 1 MIC
29 2 Cefepime =  0.12  0.015  0.125 1 MIC
29 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
29 2 Ceftazidime =  0.25  0.06  0.5 1 MIC
29 2 Ertapenem =  0.015  0.004  0.016 1 MIC
29 2 Imipenem =  0.12  0.06  0.25 1 MIC
29 2 Meropenem =  0.03  0.008  0.06 1 MIC
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30 1 Ampicillin = 4 2 8 1 MIC
30 1 Azithromycin = 4 - - - MIC
30 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
30 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
30 1 Chloramphenicol <= 8 2 8 1 MIC
30 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
30 1 Colistin <= 1  0.25 2 1 MIC
30 1 Gentamicin <=  0.5  0.25 1 1 MIC
30 1 Meropenem <=  0.03  0.008  0.06 1 MIC
30 1 Nalidixic acid <= 4 1 4 1 MIC
30 1 Sulfamethoxazole = 16 8 32 1 MIC
30 1 Tetracycline <= 2  0.5 2 1 MIC
30 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
30 1 Trimethoprim =  0.5  0.5 2 1 MIC
30 2 Cefepime <=  0.06  0.015  0.125 1 MIC
30 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
30 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
30 2 Cefoxitin = 2 2 8 1 MIC
30 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
30 2 Ceftazidime/clavulanic acid <=  0.12 - - - MIC
30 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
30 2 Imipenem <=  0.12  0.06  0.25 1 MIC
30 2 Meropenem <=  0.03  0.008  0.06 1 MIC
30 2 Temocillin = 8 - - - MIC
32 1 Ampicillin = 4 2 8 1 MIC
32 1 Azithromycin = 4 - - - MIC
32 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
32 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
32 1 Chloramphenicol <= 8 2 8 1 MIC
32 1 Ciprofloxacin <=  0.15  0.004  0.016 1 MIC
32 1 Colistin <= 1  0.25 2 1 MIC
32 1 Gentamicin <=  0.5  0.25 1 1 MIC
32 1 Meropenem <=  0.03  0.008  0.06 1 MIC
32 1 Nalidixic acid <= 4 1 4 1 MIC
32 1 Sulfamethoxazole = 16 8 32 1 MIC
32 1 Tetracycline <= 2  0.5 2 1 MIC
32 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
32 1 Trimethoprim =  0.5  0.5 2 1 MIC
32 2 Cefepime <=  0.06  0.015  0.125 1 MIC
32 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
32 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
32 2 Cefoxitin = 4 2 8 1 MIC
32 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
32 2 Ceftazidime/clavulanic acid <=  0.12 - - - MIC
32 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
32 2 Imipenem =  0.25  0.06  0.25 1 MIC
32 2 Meropenem <=  0.03  0.008  0.06 1 MIC
32 2 Temocillin = 8 - - - MIC
33 1 Ampicillin = 4 2 8 1 MIC
33 1 Azithromycin = 4 - - - MIC
33 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
33 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
33 1 Chloramphenicol <= 8 2 8 1 MIC
33 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
33 1 Colistin <= 1  0.25 2 1 MIC
33 1 Gentamicin <=  0.5  0.25 1 1 MIC
33 1 Meropenem <=  0.03  0.008  0.06 1 MIC
33 1 Nalidixic acid <= 4 1 4 1 MIC
33 1 Sulfamethoxazole = 32 8 32 1 MIC
33 1 Tetracycline <= 2  0.5 2 1 MIC
33 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
33 1 Trimethoprim =  0.5  0.5 2 1 MIC
33 2 Cefepime <=  0.06  0.015  0.125 1 MIC
33 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
33 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
33 2 Cefoxitin = 4 2 8 1 MIC
33 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
33 2 Ceftazidime/clavulanic acid <=  0.12 - - - MIC
33 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
33 2 Imipenem =  0.25  0.06  0.25 1 MIC
33 2 Meropenem <=  0.03  0.008  0.06 1 MIC
33 2 Temocillin = 8 - - - MIC
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34 1 Ampicillin = 4 2 8 1 MIC
34 1 Azithromycin = 4 - - - MIC
34 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
34 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
34 1 Chloramphenicol <= 8 2 8 1 MIC
34 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
34 1 Colistin <= 1  0.25 2 1 MIC
34 1 Gentamicin <=  0.5  0.25 1 1 MIC
34 1 Meropenem <=  0.03  0.008  0.06 1 MIC
34 1 Nalidixic acid <= 4 1 4 1 MIC
34 1 Sulfamethoxazole = 16 8 32 1 MIC
34 1 Tetracycline <= 2  0.5 2 1 MIC
34 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
34 1 Trimethoprim =  0.5  0.5 2 1 MIC
34 2 Cefepime <=  0.06  0.015  0.125 1 MIC
34 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
34 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
34 2 Cefoxitin = 4 2 8 1 MIC
34 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
34 2 Ceftazidime/clavulanic acid <=  0.12 - - - MIC
34 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
34 2 Imipenem <=  0.12  0.06  0.25 1 MIC
34 2 Meropenem <=  0.03  0.008  0.06 1 MIC
34 2 Temocillin = 16 - - - MIC
36 1 Ampicillin = 4 2 8 1 MIC
36 1 Azithromycin <= 2 - - - MIC
36 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
36 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
36 1 Chloramphenicol <= 8 2 8 1 MIC
36 1 Ciprofloxacin =  0.03  0.004  0.016 0 MIC
36 1 Colistin <= 1  0.25 2 1 MIC
36 1 Gentamicin = 1  0.25 1 1 MIC
36 1 Meropenem <=  0.03  0.008  0.06 1 MIC
36 1 Nalidixic acid <= 4 1 4 1 MIC
36 1 Sulfamethoxazole <= 8 8 32 1 MIC
36 1 Tetracycline <= 2  0.5 2 1 MIC
36 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
36 1 Trimethoprim <=  0.25  0.5 2 0 MIC
36 2 Cefepime <=  0.06  0.015  0.125 1 MIC
36 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
36 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
36 2 Cefoxitin = 4 2 8 1 MIC
36 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
36 2 Ceftazidime/clavulanic acid <=  0.12 - - - MIC
36 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
36 2 Imipenem <=  0.12  0.06  0.25 1 MIC
36 2 Meropenem <=  0.03  0.008  0.06 1 MIC
36 2 Temocillin = 16 - - - MIC
37 1 Ampicillin = 4 2 8 1 AGA
37 1 Azithromycin = 4 - - - AGA
37 1 Cefotaxime <=  0.25  0.03  0.125 1 AGA
37 1 Ceftazidime <=  0.5  0.06  0.5 1 AGA
37 1 Chloramphenicol <= 8 2 8 1 AGA
37 1 Ciprofloxacin <=  0.015  0.004  0.016 1 AGA
37 1 Colistin <= 1  0.25 2 1 AGA
37 1 Gentamicin <=  0.5  0.25 1 1 AGA
37 1 Meropenem <=  0.03  0.008  0.06 1 AGA
37 1 Nalidixic acid <= 4 1 4 1 AGA
37 1 Sulfamethoxazole = 32 8 32 1 AGA
37 1 Tetracycline <= 2  0.5 2 1 AGA
37 1 Tigecycline <=  0.25  0.03  0.25 1 AGA
37 1 Trimethoprim = 1  0.5 2 1 AGA
37 2 Cefepime =  0.03  0.015  0.125 1 AGA
37 2 Cefotaxime <=  0.25  0.03  0.125 1 AGA
37 2 Cefotaxime/clavulanic acid <=  0.06 - - - AGA
37 2 Cefoxitin = 4 2 8 1 AGA
37 2 Ceftazidime <=  0.25  0.06  0.5 1 AGA
37 2 Ceftazidime/clavulanic acid <=  0.125 - - - AGA
37 2 Ertapenem <=  0.015  0.004  0.016 1 AGA
37 2 Imipenem <=  0.125  0.06  0.25 1 AGA
37 2 Meropenem <=  0.03  0.008  0.06 1 AGA
37 2 Temocillin = 2 - - - AGA
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39 1 Ampicillin = 4 2 8 1 MIC
39 1 Azithromycin = 4 - - - MIC
39 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
39 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
39 1 Chloramphenicol <= 8 2 8 1 MIC
39 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
39 1 Colistin <= 1  0.25 2 1 MIC
39 1 Gentamicin <=  0.5  0.25 1 1 MIC
39 1 Meropenem <=  0.03  0.008  0.06 1 MIC
39 1 Nalidixic acid <= 4 1 4 1 MIC
39 1 Sulfamethoxazole = 16 8 32 1 MIC
39 1 Tetracycline <= 2  0.5 2 1 MIC
39 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
39 1 Trimethoprim =  0.5  0.5 2 1 MIC
39 2 Cefepime =  0.06  0.015  0.125 1 MIC
39 2 Cefotaxime =  0.25  0.03  0.125 0 MIC
39 2 Cefoxitin = 4 2 8 1 MIC
39 2 Ceftazidime =  0.25  0.06  0.5 1 MIC
39 2 Ertapenem =  0.015  0.004  0.016 1 MIC
39 2 Imipenem =  0.25  0.06  0.25 1 MIC
39 2 Meropenem =  0.03  0.008  0.06 1 MIC
39 2 Temocillin = 16 - - - MIC
40 1 Ampicillin = 2 2 8 1 MIC
40 1 Cefotaxime =  0.12  0.03  0.125 1 MIC
40 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
40 1 Chloramphenicol <= 8 2 8 1 MIC
40 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
40 1 Colistin <= 1  0.25 2 1 MIC
40 1 Gentamicin <=  0.5  0.25 1 1 MIC
40 1 Meropenem <=  0.03  0.008  0.06 1 MIC
40 1 Nalidixic acid <= 4 1 4 1 MIC
40 1 Sulfamethoxazole = 16 8 32 1 MIC
40 1 Tetracycline <= 2  0.5 2 1 MIC
40 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
40 1 Trimethoprim =  0.5  0.5 2 1 MIC
40 2 Cefepime <=  0.06  0.015  0.125 1 MIC
40 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
40 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
40 2 Cefoxitin = 2 2 8 1 MIC
40 2 Ceftazidime =  0.5  0.06  0.5 1 MIC
40 2 Ceftazidime/clavulanic acid <=  0.12 - - - MIC
40 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
40 2 Imipenem <=  0.12  0.06  0.25 1 MIC
40 2 Meropenem <=  0.03  0.008  0.06 1 MIC
42 1 Ampicillin = 4 2 8 1 MIC
42 1 Azithromycin = 8 - - - MIC
42 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
42 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
42 1 Chloramphenicol <= 8 2 8 1 MIC
42 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
42 1 Colistin <= 1  0.25 2 1 MIC
42 1 Gentamicin <=  0.5  0.25 1 1 MIC
42 1 Meropenem <=  0.03  0.008  0.06 1 MIC
42 1 Nalidixic acid <= 4 1 4 1 MIC
42 1 Sulfamethoxazole = 64 8 32 0 MIC
42 1 Tetracycline <= 2  0.5 2 1 MIC
42 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
42 1 Trimethoprim = 1  0.5 2 1 MIC
42 2 Cefepime <=  0.06  0.015  0.125 1 MIC
42 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
42 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
42 2 Cefoxitin = 4 2 8 1 MIC
42 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
42 2 Ceftazidime/clavulanic acid <=  0.125 - - - MIC
42 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
42 2 Imipenem =  0.25  0.06  0.25 1 MIC
42 2 Meropenem <=  0.03  0.008  0.06 1 MIC
42 2 Temocillin = 8 - - - MIC
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45 1 Ampicillin = 4 2 8 1 MIC
45 1 Azithromycin = 4 - - - MIC
45 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
45 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
45 1 Chloramphenicol <= 8 2 8 1 MIC
45 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
45 1 Colistin <= 1  0.25 2 1 MIC
45 1 Gentamicin <=  0.5  0.25 1 1 MIC
45 1 Meropenem <=  0.03  0.008  0.06 1 MIC
45 1 Nalidixic acid <= 4 1 4 1 MIC
45 1 Sulfamethoxazole = 32 8 32 1 MIC
45 1 Tetracycline <= 2  0.5 2 1 MIC
45 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
45 1 Trimethoprim = 1  0.5 2 1 MIC
45 2 Cefepime <=  0.06  0.015  0.125 1 MIC
45 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
45 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
45 2 Cefoxitin = 4 2 8 1 MIC
45 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
45 2 Ceftazidime/clavulanic acid <=  0.12 - - - MIC
45 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
45 2 Imipenem <=  0.12  0.06  0.25 1 MIC
45 2 Meropenem <=  0.03  0.008  0.06 1 MIC
45 2 Temocillin = 16 - - - MIC
56 1 Ampicillin = 4 2 8 1 MIC
56 1 Azithromycin = 4 - - - MIC
56 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
56 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
56 1 Chloramphenicol <= 8 2 8 1 MIC
56 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
56 1 Colistin <= 1  0.25 2 1 MIC
56 1 Gentamicin <=  0.5  0.25 1 1 MIC
56 1 Meropenem <=  0.03  0.008  0.06 1 MIC
56 1 Nalidixic acid <= 4 1 4 1 MIC
56 1 Sulfamethoxazole = 16 8 32 1 MIC
56 1 Tetracycline <= 2  0.5 2 1 MIC
56 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
56 1 Trimethoprim = 1  0.5 2 1 MIC
56 2 Cefepime <=  0.06  0.015  0.125 1 MIC
56 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
56 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
56 2 Cefoxitin = 2 2 8 1 MIC
56 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
56 2 Ceftazidime/clavulanic acid <=  0.12 - - - MIC
56 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
56 2 Imipenem <=  0.12  0.06  0.25 1 MIC
56 2 Meropenem <=  0.03  0.008  0.06 1 MIC
56 2 Temocillin = 4 - - - MIC
58 1 Ampicillin = 8 2 8 1 MIC
58 1 Azithromycin = 8 - - - MIC
58 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
58 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
58 1 Chloramphenicol <= 8 2 8 1 MIC
58 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
58 1 Colistin <= 1  0.25 2 1 MIC
58 1 Gentamicin <=  0.5  0.25 1 1 MIC
58 1 Meropenem <=  0.03  0.008  0.06 1 MIC
58 1 Nalidixic acid <= 4 1 4 1 MIC
58 1 Sulfamethoxazole = 32 8 32 1 MIC
58 1 Tetracycline <= 2  0.5 2 1 MIC
58 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
58 1 Trimethoprim = 1  0.5 2 1 MIC
58 2 Cefepime <=  0.06  0.015  0.125 1 MIC
58 2 Cefotaxime <=  0.25  0.03  0.125 1 MIC
58 2 Cefotaxime/clavulanic acid <=  0.06 - - - MIC
58 2 Cefoxitin = 4 2 8 1 MIC
58 2 Ceftazidime <=  0.25  0.06  0.5 1 MIC
58 2 Ceftazidime/clavulanic acid =  0.25 - - - MIC
58 2 Ertapenem <=  0.015  0.004  0.016 1 MIC
58 2 Imipenem <=  0.12  0.06  0.25 1 MIC
58 2 Meropenem <=  0.03  0.008  0.06 1 MIC
58 2 Temocillin = 16 - - - MIC
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60 1 Ampicillin = 4 2 8 1 MIC
60 1 Azithromycin = 4 - - - MIC
60 1 Cefotaxime <=  0.25  0.03  0.125 1 MIC
60 1 Ceftazidime <=  0.5  0.06  0.5 1 MIC
60 1 Chloramphenicol <= 8 2 8 1 MIC
60 1 Ciprofloxacin <=  0.015  0.004  0.016 1 MIC
60 1 Colistin <= 1  0.25 2 1 MIC
60 1 Gentamicin <=  0.5  0.25 1 1 MIC
60 1 Meropenem <=  0.03  0.008  0.06 1 MIC
60 1 Nalidixic acid <= 4 1 4 1 MIC
60 1 Sulfamethoxazole <= 8 8 32 1 MIC
60 1 Tetracycline <= 2  0.5 2 1 MIC
60 1 Tigecycline <=  0.25  0.03  0.25 1 MIC
60 1 Trimethoprim <=  0.25  0.5 2 0 MIC
MIC: Microbroth dilution
AGA: Agar dilution
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Test results from the reference strain C. jejuni ATCC 33560
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method 36-37ºC/48h 42ºC/24h
2 Ciprofloxacin = 0.12 0.06 0.25 1 MIC X
2 Erythromycin = 1 0.5 2 1 MIC X
2 Gentamicin = 0.25 0.5 2 0 MIC X
2 Nalidixic acid = 8 4 16 1 MIC X
2 Streptomycin = 1 - - - MIC X
2 Tetracycline = 2 0.25 2 1 MIC X
6 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
6 Erythromycin <= 1 0.25 2 1 MIC X
6 Gentamicin = 1 0.25 2 1 MIC X
6 Nalidixic acid = 8 4 16 1 MIC X
6 Streptomycin = 4 - - - MIC X
6 Tetracycline <= 0.5 0.25 1 1 MIC X
9 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
9 Erythromycin = 2 0.5 2 1 MIC X
9 Gentamicin = 1 0.5 2 1 MIC X
9 Nalidixic acid = 4 4 16 1 MIC X
9 Streptomycin = 1 - - - MIC X
9 Tetracycline = 1 0.25 2 1 MIC X
11 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
11 Erythromycin <= 1 0.5 2 1 MIC X
11 Gentamicin = 1 0.5 2 1 MIC X
11 Nalidixic acid = 8 4 16 1 MIC X
11 Streptomycin = 4 - - - MIC X
11 Tetracycline = 1 0.25 2 1 MIC X
12 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
12 Erythromycin <= 1 0.5 2 1 MIC X
12 Gentamicin = 2 0.5 2 1 MIC X
12 Nalidixic acid = 8 4 16 1 MIC X
12 Streptomycin = 4 - - - MIC X
12 Tetracycline <= 0.5 0.25 2 1 MIC X
14 Ciprofloxacin <= 0.125 0.03 0.125 1 MIC X
14 Erythromycin <= 1 0.25 2 1 MIC X
14 Gentamicin = 1 0.25 2 1 MIC X
14 Nalidixic acid = 8 4 16 1 MIC X
14 Streptomycin = 4 - - - MIC X
14 Tetracycline = 1 0.25 1 1 MIC X
17 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
17 Erythromycin <= 1 0.5 2 1 MIC X
17 Gentamicin = 2 0.5 2 1 MIC X
17 Nalidixic acid = 8 4 16 1 MIC X
17 Streptomycin = 8 - - - MIC X
17 Tetracycline <= 0.5 0.25 2 1 MIC X
18 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
18 Erythromycin <= 1 0.25 2 1 MIC X
18 Gentamicin = 1 0.25 2 1 MIC X
18 Nalidixic acid = 8 4 16 1 MIC X
18 Tetracycline = 1 0.25 1 1 MIC X
19 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
19 Erythromycin <= 1 0.5 2 1 MIC X
19 Gentamicin = 1 0.5 2 1 MIC X
19 Nalidixic acid = 8 4 16 1 MIC X
19 Streptomycin = 4 - - - MIC X
19 Tetracycline = 2 0.25 2 1 MIC X
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20 Ciprofloxacin = 0.25 0.03 0.125 0 MIC X
20 Erythromycin <= 1 0.25 2 1 MIC X
20 Gentamicin = 1 0.25 2 1 MIC X
20 Nalidixic acid = 8 4 16 1 MIC X
20 Streptomycin = 2 - - - MIC X
20 Tetracycline = 4 0.25 1 0 MIC X
21 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
21 Erythromycin <= 1 0.25 2 1 MIC X
21 Gentamicin = 0.5 0.25 2 1 MIC X
21 Nalidixic acid = 4 4 16 1 MIC X
21 Streptomycin = 2 - - - MIC X
21 Tetracycline <= 0.5 0.25 1 1 MIC X
22 Ciprofloxacin <= 0.06 0.03 0.125 1 MIC X
22 Erythromycin <= 1 0.25 2 1 MIC X
22 Nalidixic acid = 4 4 16 1 MIC X
22 Tetracycline = 1 0.25 1 1 MIC X
23 Ciprofloxacin = 0.12 0.03 0.125 1 MIC X
23 Erythromycin <= 0.5 0.25 2 1 MIC X
23 Gentamicin = 1 0.25 2 1 MIC X
23 Nalidixic acid = 4 4 16 1 MIC X
23 Tetracycline = 0.5 0.25 1 1 MIC X
25 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
25 Erythromycin <= 1 0.5 2 1 MIC X
25 Gentamicin = 0.25 0.5 2 0 MIC X
25 Nalidixic acid = 8 4 16 1 MIC X
25 Streptomycin = 1 - - - MIC X
25 Tetracycline = 2 0.25 2 1 MIC X
26 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
26 Erythromycin <= 1 0.5 2 1 MIC X
26 Gentamicin = 0.5 0.5 2 1 MIC X
26 Nalidixic acid = 4 4 16 1 MIC X
26 Streptomycin = 2 - - - MIC X
26 Tetracycline <= 0.5 0.25 2 1 MIC X
29 Ciprofloxacin = 0.06 0.03 0.125 1 MIC X
29 Erythromycin = 1 0.25 2 1 MIC X
29 Gentamicin = 2 0.25 2 1 MIC X
29 Nalidixic acid = 4 4 16 1 MIC X
29 Tetracycline = 0.25 0.25 1 1 MIC X
30 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
30 Erythromycin <= 1 0.5 2 1 MIC X
30 Gentamicin = 1 0.5 2 1 MIC X
30 Nalidixic acid = 8 4 16 1 MIC X
30 Streptomycin = 2 - - - MIC X
30 Tetracycline = 2 0.25 2 1 MIC X
32 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
32 Erythromycin <= 1 0.5 2 1 MIC X
32 Gentamicin = 0.5 0.5 2 1 MIC X
32 Nalidixic acid = 4 4 16 1 MIC X
32 Streptomycin = 4 - - - MIC X
32 Tetracycline = 1 0.25 2 1 MIC X
33 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
33 Erythromycin <= 1 0.5 2 1 MIC X
33 Gentamicin = 0.5 0.5 2 1 MIC X
33 Nalidixic acid = 8 4 16 1 MIC X
33 Streptomycin = 2 - - - MIC X
33 Tetracycline <= 0.5 0.25 2 1 MIC X
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34 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
34 Erythromycin <= 1 0.5 2 1 MIC X
34 Gentamicin = 0.5 0.5 2 1 MIC X
34 Nalidixic acid = 8 4 16 1 MIC X
34 Streptomycin = 0.5 - - - MIC X
34 Tetracycline = 2 0.25 2 1 MIC X
36 Ciprofloxacin <= 0.06 0.03 0.125 1 MIC X
36 Erythromycin <= 0.5 0.25 2 1 MIC X
36 Gentamicin = 2 0.25 2 1 MIC X
36 Nalidixic acid = 16 4 16 1 MIC X
36 Streptomycin = 2 - - - MIC X
36 Tetracycline <= 0.12 0.25 1 0 MIC X
37 Ciprofloxacin = 0.25 0.12 1 1 AGA X
37 Erythromycin = 2 1 8 1 AGA X
37 Gentamicin = 2 0.5 2 1 AGA X
37 Nalidixic acid = 8 - - - AGA X
37 Streptomycin = 4 - - - AGA X
37 Tetracycline = 1 - - - AGA X
39 Ciprofloxacin = 0.12 0.06 0.25 1 MIC X
39 Erythromycin = 1 0.5 2 1 MIC X
39 Gentamicin = 0.5 0.5 2 1 MIC X
39 Nalidixic acid = 8 4 16 1 MIC X
39 Tetracycline = 1 0.25 2 1 MIC X
40 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
40 Erythromycin <= 1 0.25 2 1 MIC X
40 Gentamicin = 0.25 0.25 2 1 MIC X
40 Nalidixic acid = 4 4 16 1 MIC X
40 Tetracycline <= 0.5 0.25 1 1 MIC X
42 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
42 Erythromycin <= 1 0.5 2 1 MIC X
42 Gentamicin <= 0.12 0.5 2 0 MIC X
42 Nalidixic acid = 8 4 16 1 MIC X
42 Streptomycin = 1 - - - MIC X
42 Tetracycline = 2 0.25 2 1 MIC X
45 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
45 Erythromycin <= 1 0.5 2 1 MIC X
45 Gentamicin = 1 0.5 2 1 MIC X
45 Nalidixic acid = 8 4 16 1 MIC X
45 Streptomycin = 4 - - - MIC X
45 Tetracycline = 2 0.25 2 1 MIC X
56 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
56 Erythromycin <= 1 0.5 2 1 MIC X
56 Gentamicin = 1 0.5 2 1 MIC X
56 Nalidixic acid = 8 4 16 1 MIC X
56 Streptomycin = 4 - - - MIC X
56 Tetracycline = 1 0.25 2 1 MIC X
58 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
58 Erythromycin <= 1 0.5 2 1 MIC X
58 Gentamicin = 0.5 0.5 2 1 MIC X
58 Nalidixic acid = 8 4 16 1 MIC X
58 Streptomycin = 2 - - - MIC X
58 Tetracycline <= 0.5 0.25 2 1 MIC X
60 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
60 Erythromycin <= 1 0.5 2 1 MIC X
60 Gentamicin = 1 0.5 2 1 MIC X
60 Nalidixic acid = 8 4 16 1 MIC X
60 Streptomycin = 4 - - - MIC X
60 Tetracycline = 1 0.25 2 1 MIC X
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Salmonella - expected and obtained interpretation
Antimicrobial Strain Panel Expected % R % S No. correct No. incorrect
Ampicillin AMP EURL S-10.1 Panel 1 S 0 100 31 0
EURL S-10.2 Panel 1 R 100 0 31 0
EURL S-10.3 Panel 1 R 100 0 31 0
EURL S-10.4 Panel 1 R 97 3 31 1
EURL S-10.5 Panel 1 R 100 0 31 0
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 R 97 3 31 1
EURL S-10.8 Panel 1 R 100 0 31 0
Cefotaxime FOT EURL S-10.1 Panel 1 S 0 100 31 0
EURL S-10.2 Panel 1 S 0 100 31 0
EURL S-10.3 Panel 1 R 100 0 31 0
EURL S-10.3 Panel 2 R 100 0 31 0
EURL S-10.4 Panel 1 R 100 0 31 0
EURL S-10.4 Panel 2 R 100 0 31 0
EURL S-10.5 Panel 1 S 0 100 31 0
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 R 100 0 31 0
EURL S-10.7 Panel 2 R 100 0 31 0
EURL S-10.8 Panel 1 R 100 0 31 0
EURL S-10.8 Panel 2 R 100 0 31 0
Cefoxitin FOX EURL S-10.3 Panel 2 S 0 100 31 0
EURL S-10.4 Panel 2 S 0 100 31 0
EURL S-10.7 Panel 2 S 3 97 31 1
EURL S-10.8 Panel 2 S 0 100 31 0
Ceftazidime TAZ EURL S-10.1 Panel 1 S 0 100 31 0
EURL S-10.2 Panel 1 S 0 100 31 0
EURL S-10.3 Panel 1 S 3 97 31 1
EURL S-10.3 Panel 2 S 3 97 31 1
EURL S-10.4 Panel 1 S 0 100 30 0
EURL S-10.4 Panel 2 S 0 100 31 0
EURL S-10.5 Panel 1 S 0 100 31 0
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 R 100 0 31 0
EURL S-10.7 Panel 2 R 100 0 31 0
EURL S-10.8 Panel 1 R 100 0 31 0
EURL S-10.8 Panel 2 R 100 0 31 0
Chloramphenicol CHL EURL S-10.1 Panel 1 S 0 100 31 0
EURL S-10.2 Panel 1 R 100 0 31 0
EURL S-10.3 Panel 1 S 0 100 31 0
EURL S-10.4 Panel 1 S 0 100 31 0
EURL S-10.5 Panel 1 R 97 3 31 1
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 R 100 0 31 0
EURL S-10.8 Panel 1 S 0 100 31 0
Ciprofloxacin CIP EURL S-10.1 Panel 1 S 0 100 31 0
EURL S-10.2 Panel 1 S 0 100 31 0
EURL S-10.3 Panel 1 R 94 6 31 2
EURL S-10.4 Panel 1 S 0 100 31 0
EURL S-10.5 Panel 1 S 0 100 31 0
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 R 97 3 31 1
EURL S-10.8 Panel 1 S 0 100 31 0
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Antimicrobial Strain Panel Expected % R % S No. correct No. incorrect
Colistin COL EURL S-10.1 Panel 1 R 90 10 31 3
EURL S-10.2 Panel 1 S 0 100 30 0
EURL S-10.3 Panel 1 S 3 97 31 1
EURL S-10.4 Panel 1 S 0 100 31 0
EURL S-10.5 Panel 1 S 0 100 31 0
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 S 3 97 31 1
EURL S-10.8 Panel 1 S 0 100 31 0
Ertapenem ETP EURL S-10.3 Panel 2 S 0 100 31 0
EURL S-10.4 Panel 2 R 100 0 31 0
EURL S-10.7 Panel 2 S 0 100 31 0
EURL S-10.8 Panel 2 S 0 100 31 0
Gentamicin GEN EURL S-10.1 Panel 1 S 0 100 31 0
EURL S-10.2 Panel 1 S 0 100 31 0
EURL S-10.3 Panel 1 S 3 97 31 1
EURL S-10.4 Panel 1 S 0 100 31 0
EURL S-10.5 Panel 1 S 0 100 31 0
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 R 100 0 31 0
EURL S-10.8 Panel 1 S 0 100 31 0
Imipenem IMI EURL S-10.3 Panel 2 S 0 100 31 0
EURL S-10.7 Panel 2 S 0 100 31 0
EURL S-10.8 Panel 2 S 0 100 31 0
EURL S-10.4* Panel 2 R 70 30 21 9
Meropenem MER EURL S-10.1 Panel 1 S 0 100 31 0
EURL S-10.2 Panel 1 S 0 100 31 0
EURL S-10.3 Panel 1 S 0 100 31 0
EURL S-10.3 Panel 2 S 0 100 31 0
EURL S-10.4 Panel 1 R 100 0 31 0
EURL S-10.4 Panel 2 R 100 0 31 0
EURL S-10.5 Panel 1 S 0 100 31 0
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 2 S 0 100 31 0
EURL S-10.8 Panel 1 S 0 100 31 0
EURL S-10.8 Panel 2 S 0 100 31 0
Nalidixic acid NAL EURL S-10.1 Panel 1 S 0 100 31 0
EURL S-10.2 Panel 1 S 0 100 31 0
EURL S-10.3 Panel 1 R 100 0 31 0
EURL S-10.4 Panel 1 S 3 97 31 1
EURL S-10.5 Panel 1 S 0 100 31 0
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 S 0 100 30 0
EURL S-10.8 Panel 1 S 0 100 31 0
Sulfamethoxazole SMX EURL S-10.1 Panel 1 S 0 100 30 0
EURL S-10.2 Panel 1 R 100 0 31 0
EURL S-10.3 Panel 1 S 3 97 31 1
EURL S-10.4 Panel 1 S 0 100 29 0
EURL S-10.5 Panel 1 R 100 0 31 0
EURL S-10.6 Panel 1 S 7 93 30 2
EURL S-10.7 Panel 1 R 100 0 31 0
EURL S-10.8 Panel 1 S 3 97 30 1
Tetracycline TET EURL S-10.1 Panel 1 S 0 100 31 0
EURL S-10.2 Panel 1 R 97 3 31 1
EURL S-10.3 Panel 1 R 100 0 31 0
EURL S-10.4 Panel 1 S 0 100 30 0
EURL S-10.5 Panel 1 R 100 0 31 0
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 R 100 0 31 0
EURL S-10.8 Panel 1 S 0 100 31 0
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Tigecycline TGC EURL S-10.1 Panel 1 S 0 100 29 0
EURL S-10.2 Panel 1 S 0 100 29 0
EURL S-10.3 Panel 1 S 0 100 29 0
EURL S-10.4 Panel 1 S 0 100 29 0
EURL S-10.5 Panel 1 R 85 15 26 4
EURL S-10.6 Panel 1 S 0 100 28 0
EURL S-10.7 Panel 1 S 4 96 28 1
EURL S-10.8 Panel 1 S 0 100 28 0
Trimethoprim TMP EURL S-10.1 Panel 1 S 0 100 31 0
EURL S-10.2 Panel 1 S 0 100 31 0
EURL S-10.3 Panel 1 S 0 100 31 0
EURL S-10.4 Panel 1 S 0 100 31 0
EURL S-10.5 Panel 1 R 97 3 31 1
EURL S-10.6 Panel 1 S 0 100 31 0
EURL S-10.7 Panel 1 R 100 0 31 0
EURL S-10.8 Panel 1 S 3 97 30 1
*Strain/antimicrobial-combination excluded from the evaluation
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Campylobacter  - expected and obtained interpretation
 
Antimicrobial Strain Expected % R % S No. correct
No. 
incorrect
EURL C-10.1 R 100 0 31 0
EURL C-10.2 S 0 100 31 0
EURL C-10.3 S 3 97 30 1
EURL C-10.4 S 0 100 31 0
EURL C-10.5 R 100 0 31 0
EURL C-10.6 R 100 0 31 0
EURL C-10.7 R 100 0 31 0
EURL C-10.8 R 100 0 31 0
EURL C-10.1 R 100 0 31 0
EURL C-10.2 S 0 100 31 0
EURL C-10.3 S 3 97 30 1
EURL C-10.4 R 100 0 31 0
EURL C-10.5 S 0 100 31 0
EURL C-10.6 R 100 0 31 0
EURL C-10.7 S 0 100 31 0
EURL C-10.8 R 100 0 31 0
EURL C-10.1 S 6 94 29 2
EURL C-10.2 S 0 100 31 0
EURL C-10.3 S 3 97 30 1
EURL C-10.4 S 0 100 31 0
EURL C-10.5 S 3 97 30 1
EURL C-10.6 S 3 97 30 1
EURL C-10.7 S 3 97 30 1
EURL C-10.8 R 100 0 31 0
EURL C-10.1 R 97 3 29 1
EURL C-10.2 S 3 97 30 1
EURL C-10.3 S 0 100 31 0
EURL C-10.4 S 0 100 31 0
EURL C-10.5 R 97 3 30 1
EURL C-10.6 R 97 3 30 1
EURL C-10.7 R 97 3 30 1
EURL C-10.8 R 100 0 31 0
EURL C-10.1 S 3 97 30 1
EURL C-10.2 R 94 6 29 2
EURL C-10.3 S 3 97 30 1
EURL C-10.4 S 0 100 31 0
EURL C-10.5 S 0 100 31 0
EURL C-10.6 S 3 97 29 1
EURL C-10.7 S 6 94 29 2
EURL C-10.8 R 100 0 31 0
EURL C-10.1 S 3 97 30 1
EURL C-10.2 S 0 100 31 0
EURL C-10.3 S 3 97 30 1
EURL C-10.4* S 26 74 31 8
EURL C-10.5 R 97 3 30 1
EURL C-10.6 R 100 0 31 0
EURL C-10.7 S 0 100 31 0
EURL C-10.8 R 100 0 31 0
*Strain/antimicrobial-combination excluded from the evaluation
Ciprofloxacin, CIP
Tetracycline, TET
Streptomycin, STR
Nalidixic acid, NAL
Gentamicin, GEN
Erythromycin, ERY
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Deviations - Salmonella
Lab no. Strain Panel Antimicrobial Obtained MIC value
Obtained 
interpretation
Expected 
MIC-value
Expected 
interpretation
2 EURL S-10.1 1 Colistin COL 8 S 8 R
4 EURL S-10.3 1 Ciprofloxacin CIP = 0.5 S = 0.5 R
4 EURL S-10.5 1 Tigecycline TGC 2 S 2 R
4 EURL S-10.5 1 Trimethoprim TMP > 32 S > 32 R
6 EURL S-10.4 1 Ampicillin AMP > 64 S > 64 R
6 EURL S-10.7 1 Ampicillin AMP > 64 S > 64 R
18 EURL S-10.6 1 Sulfamethoxazole SMX > 1024 R 64 S
19 EURL S-10.8 1 Sulfamethoxazole SMX 1024 R 32 S
19 EURL S-10.8 1 Trimethoprim TMP > 32 R = 0.5 S
20 EURL S-10.3 1 Gentamicin GEN <= 0.5 R 1 S
21 EURL S-10.4 1 Nalidixic acid NAL 128 R <= 4 S
22 EURL S-10.3 1 Colistin COL 8 R <= 1 S
26 EURL S-10.5 1 Tigecycline TGC 1 S 2 R
26 EURL S-10.7 1 Colistin COL 8 R <= 1 S
26 EURL S-10.7 1 Tigecycline TGC <= 0.25 R 1 S
29 EURL S-10.3 1 Ceftazidime TAZ 1 R 1 S
29 EURL S-10.3 2 Ceftazidime TAZ 1 R 1 S
36 EURL S-10.5 1 Tigecycline TGC <= 0.25 S 2 R
39 EURL S-10.3 1 Ciprofloxacin CIP = 0.5 S = 0.5 R
39 EURL S-10.4 ESBL test conclusion
39 EURL S-10.5 1 Chloramphenicol CHL 64 S 64 R
40 EURL S-10.1 1 Colistin COL 2 S 8 R
40 EURL S-10.2 1 Tetracycline TET <= 2 S 64 R
40 EURL S-10.3 1 Sulfamethoxazole SMX > 1024 R 32 S
40 EURL S-10.5 1 Tigecycline TGC 1 S 2 R
40 EURL S-10.7 1 Ciprofloxacin CIP = 0.06 S = 0.25 R
45 EURL S-10.6 1 Sulfamethoxazole SMX > 1024 R 64 S
56 EURL S-10.1 1 Colistin COL 2 S 8 R
56 EURL S-10.7 2 Cefoxitin FOX 16 R 8 S
56 EURL S-10.7 ESBL test conclusion
60 EURL S-10.3 ESBL test conclusion
Unusual phenotype Presumptive carbapenemase
Presumptive ESBL
Presumptive ESBL
Presumptive ESBL + pAmpC
Unusual phenotype
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Deviations - Campylobacter
Lab no. Strain Antimicrobial Obtained MIC value
Obtained 
interpretation
Expected 
MIC-value
Expected 
interpretation
2 EURL C-10.6 Streptomycin STR 16 R 2 S
18 EURL C-10.7 Streptomycin STR 8 R 4 S
19 EURL C-10.7 Streptomycin STR 8 R 4 S
36 EURL C-10.1 Gentamicin GEN 16 R =  0.25 S
36 EURL C-10.1 Nalidixic acid NAL 4 S >    64 R
36 EURL C-10.2 Nalidixic acid NAL > 64 R 4 S
36 EURL C-10.2 Streptomycin STR 2 S 16 R
36 EURL C-10.5 Gentamicin GEN > 16 R =  0.25 S
36 EURL C-10.5 Nalidixic acid NAL 8 S >    64 R
36 EURL C-10.6 Gentamicin GEN > 16 R =  0.5 S
36 EURL C-10.6 Nalidixic acid NAL 8 S >    64 R
36 EURL C-10.7 Gentamicin GEN 16 R =  0.5 S
36 EURL C-10.7 Nalidixic acid NAL 8 S >    64 R
39 EURL C-10.2 Streptomycin STR <= 0.5 S 16 R
39 EURL C-10.3 Ciprofloxacin CIP > 8 R <=  0.12 S
39 EURL C-10.3 Erythromycin ERY > 64 R <=     1 S
39 EURL C-10.3 Gentamicin GEN > 64 R =  0.25 S
39 EURL C-10.3 Streptomycin STR 8 R 1 S
39 EURL C-10.3 Tetracycline TET > 16 R <=  0.5 S
40 EURL C-10.5 Tetracycline TET 1 S >    64 R
42 EURL C-10.1 Gentamicin GEN = 0.5 R =  0.25 S
42 EURL C-10.1 Streptomycin STR 1 R 1 S
42 EURL C-10.1 Tetracycline TET <= 0.5 R <=  0.5 S
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Genotypic characterization (optional); obtained results
4 EURL-S10.3 CTX M-9 PCR (published) Hasman 2005. JAC 56:115‐121 ‐ ‐
4 EURL-S10.3 OXA - X PCR (published) Hasman 2005. JAC 56:115‐121  ‐ ‐
4 EURL-S10.3 SHV - X PCR (published) Arlet1997.FEMS ML. 152:163‐7 ‐ ‐
4 EURL-S10.3 TEM -1 PCR (published) Olesen 2004. MDR. 10:334‐340 ‐ ‐
4 EURL-S10.4 CTX - X PCR (published) Hasman 2005. JAC 56:115‐121 ‐ ‐
4 EURL-S10.4 IMP - X PCR (published) Poirel. 2011 Diag Micro Infect Dis.70(1):119‐23. ‐ ‐
4 EURL-S10.4 KPC - X PCR (published) Poirel. 2011 Diag Micro Infect Dis.70(1):119‐23. ‐ ‐
4 EURL-S10.4 OXA -48 PCR (published) Poirel. 2011 Diag Micro Infect Dis.70(1):119‐23. ‐ ‐
4 EURL-S10.4 SHV - X PCR (published) Arlet1997.FEMS ML. 152:163‐7 ‐ ‐
4 EURL-S10.4 TEM -1 PCR (published) Olesen 2004. MDR. 10:334‐340 ‐ ‐
4 EURL-S10.4 VIM - X PCR (published) Poirel. 2011 Diag Micro Infect Dis.70(1):119‐23. ‐ ‐
4 EURL-S10.7 CTX M-15 PCR (published) Hasman 2005. JAC 56:115‐121 ‐ ‐
4 EURL-S10.7 OXA - X PCR (published) Hasman 2005. JAC 56:115‐121  ‐ ‐
4 EURL-S10.7 SHV -12 PCR (published) Arlet1997.FEMS ML. 152:163‐7 ‐ ‐
4 EURL-S10.7 TEM -1 PCR (published) Olesen 2004. MDR. 10:334‐340 ‐ ‐
4 EURL-S10.8 CTX - X ‐ Hasman 2005. JAC 56:115‐121 ‐ ‐
4 EURL-S10.8 OXA - X ‐ Hasman 2005. JAC 56:115‐121  ‐ ‐
4 EURL-S10.8 SHV - X ‐ Arlet1997.FEMS ML. 152:163‐7 ‐ ‐
4 EURL-S10.8 TEM -52 ‐ Olesen 2004. MDR. 10:334‐340 ‐ ‐
9 EURL-S10.3 CTX M-9 PCR (published) JAC 2010;65;490‐495 ‐ ‐
9 EURL-S10.3 TEM -1 PCR (published) JAC 2010;65;490‐495 ‐ ‐
9 EURL-S10.4 OXA -48 PCR (published) JAC 2010;65;490‐495 ‐ ‐
9 EURL-S10.7 CTX M-15 PCR (published) JAC 2010;65;490‐495 ‐ ‐
9 EURL-S10.7 SHV -12 PCR (published) JAC 2010;65;490‐495 ‐ ‐
9 EURL-S10.7 TEM -1 PCR (published) JAC 2010;65;490‐495 ‐ ‐
9 EURL-S10.8 TEM -52 PCR (published) JAC 2010;65;490‐495 ‐ ‐
17 EURL-S10.3 CTX M-9 PCR (published) Paauw et al. (2006) TGGTGACAAAGAGAGTGCAACG ATCGCCGAAGGGCTGTGA
17 EURL-S10.3 TEM -1 PCR (published) Guerra et al. (2001) TTGGGTGCACGAGTGGGT GCTTCCCGGCAACAATTA
17 EURL-S10.4 OXA -48 PCR (published) Guerra et al. (2000) AGCAGCGCCAGTGCATCA GGAAACTTGGGGTCGAAT
17 EURL-S10.4 TEM -1 PCR (published) Guerra et al. (2001) TTGGGTGCACGAGTGGGT GCTTCCCGGCAACAATTA
17 EURL-S10.7 CTX M-15 PCR (published) Carrattoli et al 2008 CCCATGGTTAAAAAATCACTGC CTTAGACGGCAAAAGCGCTG
17 EURL-S10.7 SHV -12 PCR (published) Weill et al., (2004) TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC
17 EURL-S10.7 TEM -1 PCR (published) Guerra et al. (2001) TTGGGTGCACGAGTGGGT GCTTCCCGGCAACAATTA
17 EURL-S10.8 TEM -52 PCR (published) Guerra et al. (2001) TTGGGTGCACGAGTGGGT GCTTCCCGGCAACAATTA
21 EURL-S10.3 CTX M-4 PCR (published) doi: 10.1093/jac/dki412 attggaaagcgttcatcacc caaagagagtgcaacggatg
21 EURL-S10.4 OXA -48 PCR (published) doi:  10.3201/eid1710.110655 CATCAAGTTCAACCCAACCG GCGTGGTTAAGGATGAACAC
21 EURL-S10.7 CTX M-1 PCR (published) doi:10.1128/JCM.42.12.5715‐5721.2004 agccgccgacgctaataca gacgatgtcactggctgagc
21 EURL-S10.7 SHV - PCR (published) doi:10.1016/j.diagmicrobio.2006.04.016  tcƩtccgatgccgccgccagtca  gccgggƩaƩcƩaƩtgt
21 EURL-S10.8 TEM -52 PCR (in‐house) ‐ ttaccaatgcttaatca atgagtattcaacatttccg
25 EURL-S10.3 CTX M-9 PCR (in‐house) ‐ ‐ ‐
25 EURL-S10.3 TEM - PCR (in‐house) ‐ ‐ ‐
25 EURL-S10.4 OXA -48 PCR (in‐house) ‐ ‐ ‐
25 EURL-S10.4 TEM - PCR (in‐house) ‐ ‐ ‐
25 EURL-S10.7 CTX M-15 PCR (in‐house) ‐ ‐ ‐
25 EURL-S10.7 TEM - PCR (in‐house) ‐ ‐ ‐
25 EURL-S10.8 TEM -52 PCR (in‐house) ‐ ‐ ‐
32 EURL-S10.3 ACC - X PCR (published) (Hasman et al. 2005) ‐ ‐
32 EURL-S10.3 ACT - X PCR (published) Voets  et al.  2011   ‐ ‐
32 EURL-S10.3 CMY - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.3 CTX M-9 PCR (published) PediatrInfectDisJ28:814‐818 ‐ ‐
Method Reference Primer 5 3 Primer 3 5Labno Strain Genetype
Gene 
number
Not 
detected 
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Gene 
number
Not 
detected 
32 EURL-S10.3 DHA - X PCR (published) (Gonzalez‐Sanz et al.2009) ‐ ‐
32 EURL-S10.3 FOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.3 IMP - X PCR (published) L. Poirel et al 2011   ‐ ‐
32 EURL-S10.3 KPC - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.3 MOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.3 NDM - X PCR (published) L. Poirel et al 2011   ‐ ‐
32 EURL-S10.3 OXA -48 X PCR (published) Voets et al 2011   ‐ ‐
32 EURL-S10.3 OXA -10 X PCR (published) Voets  et al.  2011   ‐ ‐
32 EURL-S10.3 OXA - X PCR (published) J. Antimic.Chemothe(2009) 64 ‐ ‐
32 EURL-S10.3 SHV - X PCR (published) FEMSMicrobiolLett1997152:1637 ‐ ‐
32 EURL-S10.3 TEM* - X PCR (published) AntimicrAgentsChemotherap2009 ‐ ‐
32 EURL-S10.3 VEB - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.3 VIM - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.4 ACC - X PCR (published) Hasman et al. 2005) ‐ ‐
32 EURL-S10.4 ACT - X PCR (published) Voets  et al.  2011   ‐ ‐
32 EURL-S10.4 CMY - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.4 CTX - X PCR (published) PediatrInfectDisJ28:814‐818 ‐ ‐
32 EURL-S10.4 DHA - X PCR (published)  (Gonzalez‐Sanz et al.2009) ‐ ‐
32 EURL-S10.4 FOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.4 IMP - X PCR (published) L. Poirel et al 2011   ‐ ‐
32 EURL-S10.4 KPC - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.4 MOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.4 NDM - X PCR (published) L. Poirel et al 2011   ‐ ‐
32 EURL-S10.4 OXA -48 PCR (published) Voets  et al.  2011   ‐ ‐
32 EURL-S10.4 OXA -10 X PCR (published) J. Antimic.Chemothe(2009) 64 ‐ ‐
32 EURL-S10.4 OXA -10 X PCR (published) Voets  et al.  2011   ‐ ‐
32 EURL-S10.4 SHV - X PCR (published) FEMSMicrobiolLett1997152:1637 ‐ ‐
32 EURL-S10.4 TEM - X PCR (published) AntimicrAgentsChemotherap2009 ‐ ‐
32 EURL-S10.4 VEB - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.4 VIM - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.7 ACC - X PCR (published)  (Hasman et al. 2005) ‐ ‐
32 EURL-S10.7 ACT - X PCR (published) Voets  et al.  2011   ‐ ‐
32 EURL-S10.7 CMY - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.7 CTX M-15 PCR (published) PediatrInfectDisJ28:814‐818 ‐ ‐
32 EURL-S10.7 DHA - X PCR (published)  (Gonzalez‐Sanz et al.2009) ‐ ‐
32 EURL-S10.7 FOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.7 IMP - X PCR (published) L. Poirel et al 2011   ‐ ‐
32 EURL-S10.7 KPC - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.7 MOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.7 NDM - X PCR (published) L. Poirel et al 2011   ‐ ‐
32 EURL-S10.7 OXA -48 X PCR (published) Voets et al 2011   ‐ ‐
32 EURL-S10.7 OXA -10 X PCR (published) Voets et al 2011   ‐ ‐
32 EURL-S10.7 OXA - X PCR (published) J. Antimic.Chemothe(2009) 64 ‐ ‐
32 EURL-S10.7 SHV -12 PCR (published) FEMSMicrobiolLett1997152:1637 ‐ ‐
32 EURL-S10.7 TEM -1 PCR (published) AntimicrAgentsChemotherap2009 ‐ ‐
32 EURL-S10.7 VEB - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.7 VIM - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.8 ACC - X PCR (published)  (Hasman et al. 2005) ‐ ‐
32 EURL-S10.8 ACT - X PCR (published) Voets  et al.  2011   ‐ ‐
32 EURL-S10.8 CMY - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.8 CTX - X PCR (published) PediatrInfectDisJ28:814‐818 ‐ ‐
32 EURL-S10.8 DHA - X PCR (published)  (Gonzalez‐Sanz et al.2009) ‐ ‐
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32 EURL-S10.8 FOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.8 IMP - X PCR (published) L. Poirel et al 2011   ‐ ‐
32 EURL-S10.8 KPC - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.8 MOX - X PCR (published) A.AGE.CHEM2006.ClinMicr1999‐37 ‐ ‐
32 EURL-S10.8 NDM - X PCR (published) L. Poirel et al 2011   ‐ ‐
32 EURL-S10.8 OXA -48 X PCR (published) Voets et al 2011   ‐ ‐
32 EURL-S10.8 OXA -10 X PCR (published) Voets et al 2011   ‐ ‐
32 EURL-S10.8 OXA - X PCR (published) J. Antimic.Chemothe(2009) 64 ‐ ‐
32 EURL-S10.8 SHV - X PCR (published) FEMSMicrobiolLett1997152:1637 ‐ ‐
32 EURL-S10.8 TEM -52 PCR (published) AntimicrAgentsChemotherap2009 ‐ ‐
32 EURL-S10.8 VEB - X PCR (published) Dallanne et al 2010  ‐ ‐
32 EURL-S10.8 VIM - X PCR (published) Dallanne et al 2010  ‐ ‐
33 EURL-S10.3 CTX - PCR (published) Woodford,et al. (2006) CAAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL-S10.3 TEM - PCR (published) Fang, et al. (2008) CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL-S10.4 OXA -48 PCR (published) Poirel et al.(2011) GCGTGGTTAAGGATGAACAC CATCAAGTTCAACCCAACCG
33 EURL-S10.4 TEM - PCR (published) Fang,et al. (2008).  CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL-S10.7 CTX - PCR (published) Woodford,et al. (2006 AAAAATCACTGCGYCAGTTC AGCTTATTCATCGCCACGTT
33 EURL-S10.7 SHV - PCR (published) Fang,et al. (2008).  CTTTATCGGCCCTCACTCAA AGGTGCTCATCATGGGAAAG
33 EURL-S10.7 TEM - PCR (published) Fang,et al. (2008) CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL-S10.8 TEM - PCR (published) Fang,et al. (2008) CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
36 EURL-S10.3 CTX M-9 PCR (published) Hasman et al. JAC. 2005 Jul;56(1):115‐21 ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL-S10.3 SHV - X PCR (published) Briñas et al. AAC. 2002 Oct;46(10):3156‐63 CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL-S10.3 TEM -1 PCR (published) Briñas et al. AAC. 2002 Oct;46(10):3156‐63 TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
36 EURL-S10.4 CTX - X PCR (published) Hasman et al. JAC 2005 Jul;56(1):115‐21 ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL-S10.4 IMP - X PCR (published) Ellington JAC (2007)59(2):321‐322 GGAATAGAGTGGCTTAAYTCTC CCAAACYACTASGTTATCT
36 EURL-S10.4 NDM - X PCR (published) Mushtaq et. al. JAC (2011)66(9):2002‐2005 GGGCAGTCGCTTCCAACGGT GTAGTGCTCAGTGTCGGCAT
36 EURL-S10.4 OXA -48 PCR (published) Poirel et al. DiaMicInfDis. 2011 May;70(1):119‐23 GCGTGGTTAAGGATGAACAC CATCAAGTTCAACCCAACCG
36 EURL-S10.4 SHV - X PCR (published) Briñas et al. AAC 2002 Oct;46(10):3156‐63 CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL-S10.4 TEM -1 PCR (published) Briñas et al. AAC 2002 Oct;46(10):3156‐63 TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
36 EURL-S10.4 VIM - X PCR (published) Ellington JAC (2007)59(2):321‐322 GATGGTGTTTGGTCGCATA CGAATGCGCAGCACCAG
36 EURL-S10.7 CTX M-15 PCR (published) Hasman et al. JAC. 2005 Jul;56(1):115‐21. ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL-S10.7 SHV -12 PCR (published) Briñas et al. AAC. 2002 Oct;46(10):3156‐63. CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL-S10.7 TEM -1 PCR (published) Briñas et al. AAC. 2002 Oct;46(10):3156‐63. TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
36 EURL-S10.8 CTX - X PCR (published) Hasman et al. JAC. 2005 Jul;56(1):115‐21. ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
36 EURL-S10.8 SHV - X PCR (published) Briñas et al. AAC. 2002 Oct;46(10):3156‐63. CACTCAAGGATGTATTGTG TTAGCGTTGCCAGTGCTCG
36 EURL-S10.8 TEM -52 PCR (published) Briñas et al. AAC. 2002 Oct;46(10):3156‐63. TTCTTGAAGACGAAAGGGC ACGCTCAGTGGAACGAAAAC
59 EURL-S10.3 CTX M-9 Whole genome sequenced ‐ ‐ ‐
59 EURL-S10.3 TEM -1 Whole genome sequenced ‐ ‐ ‐
59 EURL-S10.4 OXA -48 Whole genome sequenced ‐ ‐ ‐
59 EURL-S10.4 TEM -1 Whole genome sequenced ‐ ‐ ‐
59 EURL-S10.7 CTX M-15 Whole genome sequenced ‐ ‐ ‐
59 EURL-S10.7 SHV -12 Whole genome sequenced ‐ ‐ ‐
59 EURL-S10.7 TEM -1 Whole genome sequenced ‐ ‐ ‐
59 EURL-S10.8 TEM -52 Whole genome sequenced ‐ ‐ ‐
Legend: 
Fields shaded grey indicate that the gene was expected
Genes in bold and white font, were detected but not expected 
*TEM-1 does not confer ESBL-production and is as such not included as an expected result. TEM-1 was, however, present in S-10.3, S-10.4 and S-10.7
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Genotypic characterization (optional); comments by participants
4 S‐9.5 TEM‐1 detected
4 S‐9.5 TEM‐1 detected
17 S‐9.3
All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. CTX‐M9 
primer is group specific, validation was done via sequencing TEM‐1 was additionally found, it's just added 
for additional information, not as ESBL‐gene
17 S‐9.3
All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. CTX‐M9 
primer is group specific, validation was done via sequencing TEM‐1 was additionally found, it's just added 
for additional information, not as ESBL‐gene
17 S‐9.3
All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. CTX‐M9 
primer is group specific, validation was done via sequencing TEM‐1 was additionally found, it's just added 
for additional information, not as ESBL‐gene
17 S‐9.4
All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. 
Validation was done via sequencing TEM‐1 was additionally found, it's just added for additional 
information, not as ESBL‐gene
17 S‐9.4
All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. 
Validation was done via sequencing TEM‐1 was additionally found, it's just added for additional 
information, not as ESBL‐gene
17 S‐9.4
All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. 
Validation was done via sequencing TEM‐1 was additionally found, it's just added for additional 
information, not as ESBL‐gene
17 S‐9.7 All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. All used primers are specific for a respective group of genes, validation was done via sequencing TEM‐1 was 
additionally found, it's just added for additional information, not as ESBL‐gene
17 S‐9.7 All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. All used primers are specific for a respective group of genes, validation was done via sequencing TEM‐1 was 
additionally found, it's just added for additional information, not as ESBL‐gene
17 S‐9.7 All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. All used primers are specific for a respective group of genes, validation was done via sequencing TEM‐1 was 
additionally found, it's just added for additional information, not as ESBL‐gene
17 S‐9.8 All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. TEM primer is group specific, validation was done via sequencing
17 S‐9.8 All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. TEM primer is group specific, validation was done via sequencing
17 S‐9.8 All primers were 5'‐>3'. The Primer in 3'‐>5' box is the reverse complement to the original primer. TEM primer is group specific, validation was done via sequencing
21 S‐9.7 qnrB positive.
21 S‐9.7 qnrB positive.
32 S‐9.3 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.3 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.3 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.4 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.4 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.4 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.7 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.7 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.7 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.8 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.8 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.8 SPM Gene tested for/not detected (L. Poirel et al 2011)
59 S‐9.3 genenumber for genetype TEM: TEM‐1B
59 S‐9.4 genenumber for genetype TEM: TEM‐1D
59 S‐9.7 genenumber for genetype TEM: TEM‐1B
59 S‐9.8 genenumber for genetype TEM: TEM‐52B
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